var title_f31_15_31984="Nail nipper";
var content_f31_15_31984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Heavy-duty nail nipper used in trimming, paring, and nail surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31984=[""].join("\n");
var outline_f31_15_31984=null;
var title_f31_15_31985="Tubular epithelial cell cast in acute tubular necrosis";
var content_f31_15_31985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Photomicrograph showing tubular epithelial cell casts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Epithelial cell cast containing cells that are larger than white cells.",
"    <br/>",
"    (B) Epithelial cell cast with free epithelial cells (arrow) in the urine sediment. Renal tubular epithelial cells are larger than white cell and have a single, large central nucleus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31985=[""].join("\n");
var outline_f31_15_31985=null;
var title_f31_15_31986="Duodenal vessel after Rx Endosc";
var content_f31_15_31986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Combination therapy for a bleeding duodenal ulcer with a visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Appearance of a duodenal ulcer that had a visible vessel following injection therapy with epinephrine and thermal coagulation. Note that the visible vessel has been flattened.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31986=[""].join("\n");
var outline_f31_15_31986=null;
var title_f31_15_31987="Hydroxypropyl methylcellulose: Patient drug information";
var content_f31_15_31987=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydroxypropyl methylcellulose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/35/43570?source=see_link\">",
"     see \"Hydroxypropyl methylcellulose: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cellugel&reg;;",
"     </li>",
"     <li>",
"      GenTeal&reg; Mild [OTC];",
"     </li>",
"     <li>",
"      GenTeal&reg; [OTC];",
"     </li>",
"     <li>",
"      Gonak&trade;;",
"     </li>",
"     <li>",
"      Goniosoft&trade; [OTC];",
"     </li>",
"     <li>",
"      Isopto&reg; Tears [OTC];",
"     </li>",
"     <li>",
"      Natural Balance Tears [OTC];",
"     </li>",
"     <li>",
"      Nature's Tears [OTC];",
"     </li>",
"     <li>",
"      Tears Again&reg; MC Gel Drops&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Genteal&reg;;",
"     </li>",
"     <li>",
"      Isopto&reg; Tears",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydroxypropyl methylcellulose or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11967 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31987=[""].join("\n");
var outline_f31_15_31987=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180950\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180951\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016739\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016738\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016743\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016744\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016746\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016741\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016742\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016747\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016748\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/35/43570?source=related_link\">",
"      Hydroxypropyl methylcellulose: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31988="Human chorionic gonadotropin: Patient drug information";
var content_f31_15_31988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Human chorionic gonadotropin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"     see \"Human chorionic gonadotropin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/25/33171?source=see_link\">",
"     see \"Human chorionic gonadotropin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Novarel&reg;;",
"     </li>",
"     <li>",
"      Pregnyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chorionic Gonadotropin for Injection;",
"     </li>",
"     <li>",
"      Pregnyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help make sperm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691805",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat delays in a man's growth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chorionic gonadotropin (human) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ovarian cysts or a cancer where hormones make it grow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If a child is using and has started puberty.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of getting pregnant with more than one baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ovarian cyst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699073",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of puberty. These include pimples, voice changes, sudden rise in height, or facial hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11606 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31988=[""].join("\n");
var outline_f31_15_31988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151099\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151100\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017670\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017669\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017674\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017675\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017677\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017672\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017673\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017678\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017679\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=related_link\">",
"      Human chorionic gonadotropin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/25/33171?source=related_link\">",
"      Human chorionic gonadotropin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31989="Tracheoplasty surgery";
var content_f31_15_31989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheoplasty surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tracheobronchoplasty-appearance from the surgeon's viewpoint. Polypropylene mesh has been fully sutured to the airway.",
"    <div class=\"footnotes\">",
"     Large single arrow: row of blue non-absorbable sutures; small double arrows: vagus nerve crossing posterior trachea; L MSB: left mainstem bronchus; R MSB: right mainstem bronchus.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sidhu P Gangadharan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31989=[""].join("\n");
var outline_f31_15_31989=null;
var title_f31_15_31990="Trifluoperazine: Pediatric drug information";
var content_f31_15_31990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trifluoperazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/2/19495?source=see_link\">",
"    see \"Trifluoperazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/39/41588?source=see_link\">",
"    see \"Trifluoperazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trifluoperazine&reg;;",
"     </li>",
"     <li>",
"      Novo-Trifluzine;",
"     </li>",
"     <li>",
"      PMS-Trifluoperazine;",
"     </li>",
"     <li>",
"      Terfluzine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1040677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1040705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/2/19495?source=see_link\">",
"      see \"Trifluoperazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Schizophrenia/psychoses (",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be individualized; use lowest effective dose and shortest effective duration; periodically reassess the need for continued treatment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;6 years: Dosage not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: Hospitalized or well-supervised patients: Initial: 1 mg 1-2 times/day; gradually increase dose until symptoms are controlled or adverse effects have become troublesome; maintenance: 1-15 mg/day in 1-2 divided doses (maximum: 15 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inpatient: Initial: 2-5 mg twice daily; gradually increase dose; usual maintenance: 15-20 mg/day in 2 divided doses (maximum: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Outpatient: Initial: 1-3 mg twice daily (maximum: 6 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inpatient: Initial: 2-5 mg twice daily; gradually increase dose; usual maintenance: 15-20 mg/day in 2 divided doses (maximum dose: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Outpatient: Initial: 1-3 mg twice daily (maximum: 40 mg/day; exceptions occur-indication specific)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonpsychotic anxiety: Adults: 1-2 mg twice daily; maximum: 6 mg/day; therapy for anxiety should not exceed 12 weeks; do not exceed 6 mg/day for longer than 12 weeks when treating anxiety; agitation, jitteriness, or insomnia may be confused with original neurotic or psychotic symptoms",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5722883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI upset; do not take within 2 hours of any antacids",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5722849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in tight, light-resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1040678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia (FDA approved in ages &ge;6 years and adults); short-term treatment of generalized nonpsychotic anxiety (not a drug of choice) (FDA approved in adults); also used for management of psychotic disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trifluoperazine may be confused with trihexyphenidyl",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Stelazine may be confused with selegiline",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypotension, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness; extrapyramidal symptoms (akathisia, dystonias, pseudoparkinsonism, tardive dyskinesia); headache, impairment of temperature regulation, lowering of seizure threshold, neuroleptic malignant syndrome (NMS)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration of skin (blue-gray), increased sensitivity to sun, photosensitivity, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, galactorrhea, gynecomastia, hyperglycemia, hypoglycemia, lactation, libido (changes in), menstrual cycle (changes in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, stomach pain, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficulty in urination, ejaculatory disturbances, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cornea and lens changes, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1040682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trifluoperazine or any component; cross-sensitivity with other phenothiazines may exist; severe CNS depression; bone marrow suppression; blood dyscrasias; severe hepatic disease; coma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5722847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hemodynamic instability; predisposition to seizures; subcortical brain damage; hepatic impairment; severe cardiac, renal, or respiratory disease. May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving); use with caution in disorders where CNS depression is a feature. Use with caution in Parkinson's disease. Esophageal dysmotility and aspiration have been associated with antipsychotic use; use with caution in patients at risk of pneumonia. Use with caution in breast cancer or other prolactin-dependent tumors (may elevate prolactin levels). May alter temperature regulation (use with caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects). May mask toxicity of other drugs due to antiemetic effects. May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines. May cause orthostatic hypotension; use with caution in patients at risk of this effect or those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, or other medications which may predispose). Trifluoperazine has not been shown to be effective for the treatment of behavioral complications in patients with mental retardation. Safety and efficacy in children &lt;6 years of age have not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cholestatic jaundice, liver damage, and hepatitis may occur; obtain appropriate liver tests if patient develops fever with grippe-like symptoms; discontinue treatment if liver tests are abnormal. Phenothiazines may cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); therefore, they should be used with caution in patients with decreased GI motility, urinary retention, benign prostatic hypertrophy, xerostomia, or visual problems. Conditions which also may be exacerbated by cholinergic blockade include narrow-angle glaucoma (screening is recommended) and worsening of myasthenia gravis. Relative to other antipsychotics, trifluoperazine has a low potency of cholinergic blockade.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1040683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is high relative to other typical antipsychotics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients). May be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia). Safety for use during pregnancy has not been established; prolonged jaundice, hyper-reflexia, hyporeflexia, or extrapyramidal signs may occur in newborn infants of mothers who received phenothiazines; clinical benefits should clearly outweigh risks before initiating use during pregnancy. May cause pigmentary retinopathy (discontinue drug if ophthalmoscopic or visual field exam demonstrates retinal changes).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Thrombocytopenia, anemia, agranulocytosis, and pancytopenia have been reported with trifluoperazine use. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Use is contraindicated in patients with existing blood dyscrasias or bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; trifluoperazine is not approved for this indication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5722848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause increase in dietary riboflavin requirements",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10927364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies, except when using doses that were also maternally toxic. Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1040711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; periodic eye exam, CBC with differential, liver enzyme tests; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; therapeutic response (mental status, mood, affect, gait), and adverse reactions at beginning of therapy and periodically with long-term use [eg, excess sedation, extrapyramidal symptoms, tardive dyskinesia, CNS changes, abnormal involuntary movement scale (AIMS)]",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1040699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trifluoperazine is a piperazine phenothiazine antipsychotic which is thought to improve psychosis by blocking postsynaptic mesolimbic dopaminergic receptors in the brain; adverse effects are associated with postsynaptic dopaminergic blockade in nigrostriatal and tuberoinfundibular dopaminergic tracts. It depresses the release of hypothalamic and hypophyseal hormones and exhibits alpha-adrenergic blocking effect. Blockade of muscarinic cholinergic receptors is low but may be significant for some patients.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5170579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: For control of agitation, aggression, hostility: 2-4 weeks; for control of psychotic symptoms (hallucinations, disorganized thinking or behavior, delusions): Within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adequate trial: 6 weeks at moderate to high dose based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Variable",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1040702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: &gt;24 hours with chronic use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1040715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/39/41588?source=see_link\">",
"      see \"Trifluoperazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use exactly as directed; do not increase dose or frequency. Do not discontinue without consulting prescriber. Avoid alcohol, caffeine, and other prescription or nonprescription medications not approved by prescriber. May cause drowsiness, dizziness, lightheadedness, or blurred vision, and impair ability to perform activities requiring mental alertness or physical coordination (use caution driving or when engaging in tasks requiring alertness until response to drug is known). May cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen (broad-spectrum sunscreen or physical sunscreen [preferred] or sunblock with SPF &ge;15); contact physician if reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Maintain adequate hydration unless instructed to restrict fluid intake. May cause nausea or vomiting (small frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help); constipation; postural hypotension (use caution climbing stairs or when changing position from lying or sitting to standing); urinary retention (void before taking medication); or decreased perspiration (avoid strenuous exercise in hot environments). Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual movements, anxiety, abnormal thoughts, confusion, personality changes); chest pain, palpitations, rapid heartbeat, severe dizziness; unresolved urinary retention or changes in urinary pattern; altered menstrual pattern, changes in libido, swelling or pain in breasts (male or female); vision changes; skin rash, irritation, or changes in color of skin (gray-blue); or worsening of condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5722884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of trifluoperazine should be periodically re-evaluated in patients receiving the drug for extended periods; consideration should be given whether to decrease the maintenance dose or discontinue drug therapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/15/31990/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miyamoto S, Duncan GE, Marx CE, et al, \"Treatments for Schizophrenia: A Critical Review of Pharmacology and Mechanisms of Action of Antipsychotic Drugs,\"",
"      <i>",
"       Mol Psychiatry",
"      </i>",
"      , 2005, 10(1):79-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/15/31990/abstract-text/15289815/pubmed\" id=\"15289815\" target=\"_blank\">",
"        15289815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Remington G, \"Tardive Dyskinesia: Eliminated, Forgotten, or Overshadowed?\"",
"      <i>",
"       Curr Opin Psychiatry",
"      </i>",
"      , 2007, 20(2):131-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/15/31990/abstract-text/17278910/pubmed\" id=\"17278910\" target=\"_blank\">",
"        17278910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13074 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31990=[""].join("\n");
var outline_f31_15_31990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290572\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040677\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040705\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231022\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231006\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722883\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722849\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040678\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231086\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231084\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040682\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722847\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040683\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231073\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231015\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722848\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927364\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040711\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040699\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5170579\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040702\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040715\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722884\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13074|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/2/19495?source=related_link\">",
"      Trifluoperazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/39/41588?source=related_link\">",
"      Trifluoperazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31991="What do patients need to know about their asthma?";
var content_f31_15_31991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What do patients need to know about their asthma?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     William Bailey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Andrea J Apter, MD, MSc, MA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31991/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/15/31991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of publications that describe what patients need to know about their asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Perhaps the most important and far-reaching document on what to include in an asthma education program has been \"the National Asthma Education and Prevention Program: Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma -- Full Report 2007\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1\">",
"     1",
"    </a>",
"    ]. The full text is available at the website of the National Heart, Lung, and Blood Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A comprehensive asthma education program covering all asthma education topics in depth may not be possible in all clinical settings. Based on a series of focus group interviews, the \"core elements\" necessary in an asthma education program have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The",
"    <strong>",
"     three topics",
"    </strong>",
"    of primary importance for patient education are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Function and appropriate use of medication",
"     </li>",
"     <li>",
"      Pathophysiology of asthma",
"     </li>",
"     <li>",
"      Issues in the prevention and treatment of symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Asthma Education and Prevention Program (NAEPP) has emphasized that clinician care is necessary, but not sufficient to achieve asthma control. In addition, the patient must be taught to perform effective self-management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1\">",
"     1",
"    </a>",
"    ]. The essentials of what patients need to know about their asthma will be reviewed here. An overview of asthma management and the techniques of using inhaler devices are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is ample evidence that asthma education results in a variety of patient- and society-important outcomes, including the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/11-23\">",
"     11-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improved quality of life",
"     </li>",
"     <li>",
"      Improvement in symptoms",
"     </li>",
"     <li>",
"      Fewer limitations in activity",
"     </li>",
"     <li>",
"      Improved medication adherence",
"     </li>",
"     <li>",
"      Fewer urgent care visits and hospitalizations",
"     </li>",
"     <li>",
"      Reduction in asthma-related costs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ESTABLISHING A PARTNERSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should make efforts to establish open communication and a sense of shared responsibility by doing the following at every asthma visit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involve the patient and family in decision making",
"     </li>",
"     <li>",
"      Encourage the patient and family in their self-management efforts",
"     </li>",
"     <li>",
"      Ask openly about patient preferences and goals and incorporate these into treatment when possible",
"     </li>",
"     <li>",
"      Enquire about patient and family concerns and fears about chronic illness, medication use, dependency, and cost",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASTHMA ACTION PLANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An \"asthma action plan\" is a written document that provides instructions for the patient to follow at home. It should include directions about daily self-assessment and baseline medications, as well as a plan for managing exacerbations, including peak expiratory flow (PEF) levels and symptoms for which acute care is needed (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"mobipreview.htm?36/39/37498\">",
"     form 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"mobipreview.htm?19/23/19829\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1\">",
"     1",
"    </a>",
"    ]. The action plan should be simple and formatted for ease of reading and the possibility that a patient&rsquo;s literacy level is low.",
"   </p>",
"   <p>",
"    The plan should be individualized during initial visits in consultation with the patient. During a patient's first visit, information regarding medications, treatment goals, how following the plan will help the patient reach these goals, and when to seek urgent care can be incorporated into the plan. For those patients who have or will be provided with a peak flow meter, the concepts of personal best peak flow rate and how this measurement is used should be discussed. The patient should receive a chart to record peak flow rates. At a subsequent visit, the patient's personal best peak flow can be added to the plan. Specific instructions for creating an individualized asthma action plan, as well as the needed charts for recording peak flows, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The plan should be reviewed and refined at subsequent follow-up visits. Emphasizing the patient's personal goals is essential to enhancing adherence. For example, ask, \"Have you had any problems taking your bronchodilator immediately before playing basketball? Has it helped you stay in the game?\". Question the patient about any aspects of the plan that were confusing or unhelpful.",
"   </p>",
"   <p>",
"    A written action plan is especially important for patients with moderate-to-severe persistent asthma and patients with a history of severe exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Daily asthma care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may monitor the status of their asthma based upon symptoms alone, or by additionally monitoring daily peak flow readings. Peak flow monitoring has not been shown to be superior to symptom-based monitoring, so either approach or a combined approach is acceptable.",
"   </p>",
"   <p>",
"    The plan should stipulate the patient&rsquo;s daily medications, including doses and frequencies. When patients are instructed to use inhaled medicines \"as needed\", the maximum number of \"puffs\" per day should be specifically stated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Attack management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should understand how to recognize early symptoms and begin therapy. They should understand the signs that are indications for emergency care and they should be encouraged to stay calm during severe exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Detecting symptoms and initiating treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress the importance of recognizing and immediately treating early warning signs and symptoms. These include a drop in peak expiratory flow rate, cough, wheeze, or other individual patterns related to shortness of breath or tightness in the chest. Give patients written instructions about when to take extra doses of quick-acting reliever medications and when to initiate a course of oral corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1\">",
"     1",
"    </a>",
"    ]. Recommend that patients try to rest and maintain adequate hydration during periods of increased symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Indications for emergency care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Describe signs that require immediate emergency medical attention, such as cyanosis, failure of medications to control symptoms, or a significant drop in peak flow rate. Stress the importance of understanding the difference between attacks they can manage on their own and those that require a patient to seek medical attention without delay. Emphasize the benefits of staying calm during a severe exacerbation.",
"   </p>",
"   <p>",
"    The asthma action plan should include emergency telephone numbers for the clinician, emergency department, rapid transportation, and",
"    <span class=\"nowrap\">",
"     family/friends",
"    </span>",
"    for aid and support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important self-management knowledge and skills can be categorized into four broad areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Understanding asthma",
"     </li>",
"     <li>",
"      Attack management",
"     </li>",
"     <li>",
"      Attack prevention",
"     </li>",
"     <li>",
"      Communication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The table shows the patient education topics outlined by the NAEPP (",
"    <a class=\"graphic graphic_table graphicRef61244 \" href=\"mobipreview.htm?28/37/29275\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Understanding asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient and family should understand the characteristics of asthma, the principles of effective treatment, the effects of various medications, and the resources available. It is recommended that the clinician provide information in the following manner:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     What is asthma?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Explain the three characteristics of asthma (",
"    <a class=\"graphic graphic_table graphicRef82191 \" href=\"mobipreview.htm?35/43/36542\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway inflammation",
"     </li>",
"     <li>",
"      Increased airway sensitivity to a number of triggers",
"     </li>",
"     <li>",
"      Temporary airflow obstruction leading to breathing difficulty",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Characteristic airway changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Describe the principal variations in airways that cause an asthma exacerbation: inflammation, bronchospasm, and excess mucus; and explain how different medications target these causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Review the five principles of effective asthma treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The need for individualized, continuing care",
"     </li>",
"     <li>",
"      The way medications work to prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      relieve symptoms",
"     </li>",
"     <li>",
"      Medication side effects and how to manage them",
"     </li>",
"     <li>",
"      Preventive treatment to reduce inflammation when symptoms are not present",
"     </li>",
"     <li>",
"      Early treatment of symptoms when present",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Patient fears concerning medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discuss and try to alleviate patients' fears about medication. These are generally related to such concerns as long-term adverse effects, toxicity, addiction, and tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Proper health care resource utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discuss when it is appropriate to call or visit the clinic, as opposed to the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Attack prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important issues include understanding the use of medications, avoidance of triggers, proper inhalation technique, the role of monitoring, and the use of premedication in specific situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Signs and symptoms of asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instruct how to recognize all possible symptoms of a potential asthma episode, such as shortness of breath, wheezing, chest tightness, and recurrent coughing. Explain how using a peak flow meter can help detect changes before symptoms are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"     \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Role of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Describe differences in bronchodilators and antiinflammatory medications and the proper use of each. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Factors that make asthma worse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Explain how to identify, avoid, eliminate, or control asthma \"triggers\". Stress that treatment measures without environmental control are ineffective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"     \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Correct inhaler use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provide skills training in using each type of inhaler prescribed (",
"    <a class=\"graphic graphic_figure graphicRef55242 \" href=\"mobipreview.htm?24/52/25417\">",
"     figure 1",
"    </a>",
"    ). Also discuss spacer devices and nebulizers if used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Describe the advantages of keeping diaries of medication use, peak flow rates, environmental exposures, symptoms, and actions taken. These data provide a valuable resource to both the clinician and patient in planning attack prevention and management strategies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"     \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Premedicating to prevent onset of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tell patients what medication measures to take when triggers cannot be avoided. For example, premedication with cromolyn sodium or beta-agonist agents prior to exercise or exposure to known allergens or irritants may prevent onset of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=see_link&amp;anchor=H9#H9\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Clinical use'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=see_link\">",
"     \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Evaluation of results of treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic clinical evaluation is necessary to assess adherence to the management plan and status of therapy goals. Discuss areas where desired outcomes are not being achieved, and change the therapy as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alleviating fears and misconceptions, encouraging family understanding and support, and developing open communication among the patient, the school, the family, and the health care team are critical to optimal management and attainment of as normal a lifestyle as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fears and misconceptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identify and help alleviate patient and family fears and misconceptions about asthma. They may need to be told that asthma is not caused by psychological factors; most asthma fatalities are due to under-treatment; asthma does not have to limit physical activity; and asthma does not necessarily lead to lung disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Family support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encourage patients to inform family members, friends, and co-workers about their asthma, at least to the extent that help can be provided if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Feelings about asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may have difficulty accepting that they have a chronic condition that can be treated but not cured. Help patients acknowledge and openly discuss their feelings, and take responsibility for managing their asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Communication with the health care team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress that patient input into the treatment plan is essential, and that open, honest communication among those involved will ensure better asthma management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Communication with the child's school",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encourage parents to inform relevant school personnel about regular and emergency care procedures (",
"    <a class=\"graphic graphic_table graphicRef82191 \" href=\"mobipreview.htm?35/43/36542\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_form graphicRef59053 graphicRef71869 graphicRef51794 \" href=\"mobipreview.htm?43/42/44714\">",
"     form 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Health promotion behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encourage patients to practice general preventive health practices that can affect physical and mental health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H839458\">",
"    <span class=\"h1\">",
"     INCORPORATING ASTHMA EDUCATION INTO PATIENT VISITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be challenging to incorporate patient-focused asthma education into patient care visits. To help individualize asthma education, the authors have developed a short questionnaire that is useful in determining a patient's strengths and weaknesses in asthma self-management knowledge and skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/24\">",
"     24",
"    </a>",
"    ]. This instrument is provided in the figure (",
"    <a class=\"graphic graphic_table graphicRef81460 \" href=\"mobipreview.htm?28/58/29612\">",
"     table 3",
"    </a>",
"    ). By using an instrument like this, busy clinicians can identify the most important points to discuss with each patient. The National Asthma Education and Prevention Program Expert Panel also has developed a strategy for building self-management education into patient care visits. This plan is provided in the figure (",
"    <a class=\"graphic graphic_table graphicRef56749 graphicRef63828 graphicRef75688 graphicRef64430 \" href=\"mobipreview.htm?25/9/25759\">",
"     table 4A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31991/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=see_link\">",
"       \"Patient information: Asthma in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=see_link\">",
"       \"Patient information: Asthma in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=see_link\">",
"       \"Patient information: How to use your dry powder inhaler (adults) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/2/16419?source=see_link\">",
"       \"Patient information: Avoiding asthma triggers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=see_link\">",
"       \"Patient information: Medicines for asthma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <strong>",
"       three topics",
"      </strong>",
"      of primary importance for patient education are the function and appropriate use of medication, the pathophysiology of asthma, and the prevention and treatment of symptoms. A comprehensive list of asthma education topics outlined by the National Asthma Education and Prevention Program is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef61244 \" href=\"mobipreview.htm?28/37/29275\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three characteristics of asthma for patients and families to understand are that airways inflammation, sensitivity to triggers, and the temporary occurrence of airflow obstruction leading to shortness of breath are all components of asthma. Understanding these characteristics provides the foundation for an understanding of asthma medications and trigger avoidance. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'What is asthma?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An \"asthma action plan\" is developed based on the collaboration between the patient (and family) and asthma care provider and includes information and guidance on routine daily care and management of exacerbations. Examples of action plans are provided in the figures (",
"      <a class=\"graphic graphic_form graphicRef55900 \" href=\"mobipreview.htm?36/39/37498\">",
"       form 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_form graphicRef71958 \" href=\"mobipreview.htm?38/15/39162\">",
"       form 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_form graphicRef59053 graphicRef71869 graphicRef51794 \" href=\"mobipreview.htm?43/42/44714\">",
"       form 2A-C",
"      </a>",
"      ). A written action plan is especially important for patients with moderate-to-severe",
"      <strong>",
"      </strong>",
"      persistent asthma and patients with a history of severe exacerbations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Asthma action plans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled medications are a key component of asthma management and correct inhaler use is essential. Patients and their families need clear instructions and demonstration of the correct use of each type of inhaler and spacer or chamber device prescribed (",
"      <a class=\"graphic graphic_figure graphicRef55242 \" href=\"mobipreview.htm?24/52/25417\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef72731 \" href=\"mobipreview.htm?24/22/24942\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58957 \" href=\"mobipreview.htm?22/4/22607\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57922 \" href=\"mobipreview.htm?41/43/42675\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69703 \" href=\"mobipreview.htm?23/21/23900\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80125 \" href=\"mobipreview.htm?10/16/10509\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58951 \" href=\"mobipreview.htm?11/51/12093\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Correct inhaler use'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=see_link\">",
"       \"The use of inhaler devices in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"       \"The use of inhaler devices in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma education also includes instruction on recognizing the various symptoms of a potential asthma episode, such as shortness of breath, wheezing, chest tightness, and coughing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Signs and symptoms of asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Explaining how to use a peak flow meter can help patients detect changes in airflow before symptoms are present and obtain objective confirmation of changes in airflow when symptoms develop. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=see_link\">",
"       \"Peak expiratory flow rate monitoring in asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/2\">",
"      Bailey WC, Clark NM, Gotsch AR, et al. Asthma prevention. Task Force on Research and Education for the Prevention and Control of Respiratory Diseases. Chest 1992; 102:216S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/3\">",
"      Clark NM, Gotsch A, Rosenstock IR. Patient, professional, and public education on behavioral aspects of asthma: a review of strategies for change and needed research. J Asthma 1993; 30:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/4\">",
"      Kotses H, Bernstein IL, Bernstein DI, et al. A self-management program for adult asthma. Part I: Development and evaluation. J Allergy Clin Immunol 1995; 95:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/5\">",
"      Wilson SR. Patient and physician behavior models related to asthma care. Med Care 1993; 31:MS49.",
"     </a>",
"    </li>",
"    <li>",
"     National Heart Lung and Blood Institute Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. National Institutes of Health, Bethesda, 1997, Pub. #97-4051.",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. J Allergy Clin Immunol 2002; 110:S141. Available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/8\">",
"      Williams SG, Schmidt DK, Redd SC, et al. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/9\">",
"      Bailey WC, Richards JM Jr, Brooks CM, et al. A randomized trial to improve self-management practices of adults with asthma. Arch Intern Med 1990; 150:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/10\">",
"      Kohler CL, Dolce JJ, Manzella BA, et al. Use of focus group methodology to develop an asthma self-management program useful for community-based medical practices. Health Educ Q 1993; 20:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/11\">",
"      Bartholomew LK, Gold RS, Parcel GS, et al. Watch, Discover, Think, and Act: evaluation of computer-assisted instruction to improve asthma self-management in inner-city children. Patient Educ Couns 2000; 39:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/12\">",
"      Cicutto L, Murphy S, Coutts D, et al. Breaking the access barrier: evaluating an asthma center's efforts to provide education to children with asthma in schools. Chest 2005; 128:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/13\">",
"      Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001; 21:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/14\">",
"      Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; :CD001117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/15\">",
"      Gibson PG, Powell H, Coughlan J, et al. Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev 2002; :CD001005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/16\">",
"      Guevara JP, Wolf FM, Grum CM, Clark NM. Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis. BMJ 2003; 326:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/17\">",
"      Krishna S, Francisco BD, Balas EA, et al. Internet-enabled interactive multimedia asthma education program: a randomized trial. Pediatrics 2003; 111:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/18\">",
"      Powell H, Gibson PG. Options for self-management education for adults with asthma. Cochrane Database Syst Rev 2003; :CD004107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/19\">",
"      Wesseldine LJ, McCarthy P, Silverman M. Structured discharge procedure for children admitted to hospital with acute asthma: a randomised controlled trial of nursing practice. Arch Dis Child 1999; 80:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/20\">",
"      Bonner S, Zimmerman BJ, Evans D, et al. An individualized intervention to improve asthma management among urban Latino and African-American families. J Asthma 2002; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/21\">",
"      Christiansen SC, Martin SB, Schleicher NC, et al. Evaluation of a school-based asthma education program for inner-city children. J Allergy Clin Immunol 1997; 100:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/22\">",
"      Clark NM, Brown R, Joseph CL, et al. Effects of a comprehensive school-based asthma program on symptoms, parent management, grades, and absenteeism. Chest 2004; 125:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/23\">",
"      Janson SL, Fahy JV, Covington JK, et al. Effects of individual self-management education on clinical, biological, and adherence outcomes in asthma. Am J Med 2003; 115:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31991/abstract/24\">",
"      Kohler CL, Davies SL, Bailey WC. How to implement an asthma education program. Clin Chest Med 1995; 16:557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 566 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31991=[""].join("\n");
var outline_f31_15_31991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTIVENESS OF EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ESTABLISHING A PARTNERSHIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASTHMA ACTION PLANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Daily asthma care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Attack management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Detecting symptoms and initiating treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Indications for emergency care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Understanding asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - What is asthma?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Characteristic airway changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Patient fears concerning medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Proper health care resource utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Attack prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Signs and symptoms of asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Role of medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Factors that make asthma worse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Correct inhaler use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Premedicating to prevent onset of symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Evaluation of results of treatment plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Communication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fears and misconceptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Family support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Feelings about asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Communication with the health care team",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Communication with the child's school",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Health promotion behaviors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H839458\">",
"      INCORPORATING ASTHMA EDUCATION INTO PATIENT VISITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/566|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/23/19829\" title=\"algorithm 1\">",
"      Home treatment of acute asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/566|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/52/25417\" title=\"figure 1\">",
"      Inhaler instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/22/24942\" title=\"figure 2\">",
"      Use of metered dose inhaler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/566|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?36/39/37498\" title=\"form 1\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?28/14/28905\" title=\"form 2A\">",
"      School action plan A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?38/31/39416\" title=\"form 2B\">",
"      School action plan B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?35/59/36794\" title=\"form 2C\">",
"      School action plan C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?38/15/39162\" title=\"form 3\">",
"      Child asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/566|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/4/22607\" title=\"picture 1\">",
"      MDI spacers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/43/42675\" title=\"picture 2\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/37/29275\" title=\"table 1\">",
"      Asthma patient teaching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/43/36542\" title=\"table 2\">",
"      Asthma education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/58/29612\" title=\"table 3\">",
"      Asthma patient needs survey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/12/11469\" title=\"table 4A\">",
"      Education at initial visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/52/32588\" title=\"table 4B\">",
"      Education at 1st follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/3/2109\" title=\"table 4C\">",
"      Education at 2nd follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/40/37516\" title=\"table 4D\">",
"      Education at subsequent visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/21/23900\" title=\"table 5\">",
"      Dry powder inhaler technique I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/16/10509\" title=\"table 6\">",
"      Dry powder inhaler technique II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/51/12093\" title=\"table 7\">",
"      Dry powder inhaler technique in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/2/16419?source=related_link\">",
"      Patient information: Avoiding asthma triggers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/26/1442?source=related_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31992="Short-term complications of the premature infant";
var content_f31_15_31992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Short-term complications of the premature infant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31992/contributors\">",
"     George T Mandy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31992/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31992/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/15/31992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity is defined as a birth that occurs before 37 completed weeks (less than 259 days) of gestation. It is associated with about one-third of all infant deaths in the United States and accounts for approximately 45 percent of children with cerebral palsy, 35 percent of children with vision impairment, and 25 percent of children with cognitive or hearing impairment.",
"   </p>",
"   <p>",
"    Complications of prematurity are the underlying reasons for the higher rate of infant mortality and morbidity in preterm infants compared to full term infants. The risk of complications increases with increasing immaturity. Thus, infants who are extremely premature, born at or before 25 weeks of gestation, have the highest mortality rate (about 50 percent) and if they survive, are at the greatest risk for severe impairment.",
"   </p>",
"   <p>",
"    Complications of the premature infant are divided into short-term complications (eg, respiratory and cardiovascular complications), which occur in the neonatal period, and long-term sequelae (eg, neurodevelopmental disabilities such as cerebral palsy) in patients who survive and are discharged from the neonatal intensive care unit (NICU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/1\">",
"     1",
"    </a>",
"    ]. Short-term complications increase the risk of long-term sequelae.",
"   </p>",
"   <p>",
"    Short-term complications of prematurity will be reviewed here. The long-term complications and the long-term health care needs of premature survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=see_link\">",
"     \"Long-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different degrees of prematurity are defined by gestational age (GA) or birth weight.",
"   </p>",
"   <p>",
"    The classification based upon GA is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Late preterm birth &ndash; GA between 34 and less than 37 weeks",
"     </li>",
"     <li>",
"      Very preterm birth &ndash; GA less than 32 weeks",
"     </li>",
"     <li>",
"      Extremely preterm birth &ndash; GA at or below 28 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Premature infants are also classified by birth weight (BW) (",
"    <a class=\"graphic graphic_table graphicRef57685 \" href=\"mobipreview.htm?1/8/1163\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birth weight (LBW) &ndash; BW less than 2500 g",
"     </li>",
"     <li>",
"      Very low birth weight (VLBW) &ndash; BW less than 1500 g",
"     </li>",
"     <li>",
"      Extremely low birth weight (ELBW) &ndash; BW less than 1000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Birth weights by percentile for the appropriate GA have been established (",
"    <a class=\"graphic graphic_table graphicRef81379 \" href=\"mobipreview.htm?10/59/11197\">",
"     table 2",
"    </a>",
"    ). The above definitions are used throughout this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, the following complications and their frequencies were seen in 8515 VLBW infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory distress &ndash; 93 percent",
"     </li>",
"     <li>",
"      Retinopathy of prematurity &ndash; 59 percent",
"     </li>",
"     <li>",
"      Patent ductus arteriosus &ndash; 46 percent",
"     </li>",
"     <li>",
"      Bronchopulmonary dysplasia &ndash; 42 percent",
"     </li>",
"     <li>",
"      Late-onset sepsis &ndash; 36 percent",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis &ndash; 11 percent",
"     </li>",
"     <li>",
"      Grade III intraventricular hemorrhage (IVH) and Grade IV IVH &ndash; 7 and 9 percent",
"     </li>",
"     <li>",
"      Periventricular leukomalacia &ndash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a population-based British study (EPICure 2 study), the survival and morbidity of 3378 births of extremely premature infants (gestational age between 22 and 26 weeks) born in 2006 were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/3\">",
"     3",
"    </a>",
"    ]. In this cohort, there were 2034 live births (60 percent of total cohort), of which 1668 (83 percent of live births) were admitted to an intensive care unit (ICU), and, in 189 cases (9 percent of live births), active stabilization was withheld in the delivery room. The survival to discharge for all live births was 51 percent, and the survival for infants admitted to ICU was 62 percent. Among the 1041 patients who survived to discharge, the following major morbidities, including their incidences, were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bronchopulmonary dysplasia (supplementary oxygen at 36 weeks postmenstrual age) &mdash; 68 percent",
"     </li>",
"     <li>",
"      Abnormal cerebral ultrasound &mdash; 13 percent",
"     </li>",
"     <li>",
"      Laser treatment for retinopathy of prematurity (ROP) &mdash; 16 percent",
"     </li>",
"     <li>",
"      Laparotomies for necrotizing enterocolitis (NEC) &mdash; 8 percent. There were no data on medical treatment for NEC.",
"     </li>",
"     <li>",
"      No major morbidity was reported in 41 percent of survivors to discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the risk of complications decreases with increasing gestational age, even moderately preterm infants are at risk for significant morbidity as illustrated from a Swedish population-based study of 6674 preterm infants with a gestational age between 30 and 34 weeks born from 2004 to 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/4\">",
"     4",
"    </a>",
"    ]. The following complications and their frequencies were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperbilirubinemia &mdash; 59 percent",
"     </li>",
"     <li>",
"      Acute respiratory disease &mdash; 28 percent",
"     </li>",
"     <li>",
"      Hypoglycemia &mdash; 16 percent",
"     </li>",
"     <li>",
"      Bacterial infection &mdash; 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial stabilization of a premature infant in the delivery room is important because proper management can reduce the risk of short-term complications. As an example, initiation of continuous positive airway pressure or the early administration of surfactant in very preterm infants can reduce the risk of respiratory distress syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43561?source=see_link\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most VLBW infants need resuscitation at birth. Among VLBW infants born in centers of the NICHD Neonatal Research Network between 1995 and 1996, 60 percent required endotracheal intubation, and 7 percent received resuscitation medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/5\">",
"     5",
"    </a>",
"    ]. The smallest infants were most likely to be depressed and require intervention. Apgar scores &le;3 at five minutes occurred in 27 percent of infants with BW 501 to 750 g, compared to 3 percent of infants weighing 1251 to 1500 g.",
"   </p>",
"   <p>",
"    For these reasons, anticipated delivery of a preterm infant should be attended by a clinician experienced in neonatal resuscitation. Facilities for assessment and stabilization should be close to the delivery area, and monitors and resuscitation equipment must be readily available. Resuscitation should follow established guidelines, including special considerations for prematurity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link&amp;anchor=H5#H5\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Preterm infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants are at risk for developing short-term complications that result from anatomic or functional immaturity during the neonatal period. The risk of developing complications increases with decreasing gestational age and birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, knowledge of the gestational age enables an assessment of the chance of survival and the likelihood of developing short-term complications. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The short-term complications are summarized in the following sections. Many of these complications are also discussed as individual topics in greater detail elsewhere in the program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid heat loss occurs in premature infants because of their relatively large body surface area and inability to produce enough heat. Heat is lost by conduction, convection, radiation, and evaporation.",
"   </p>",
"   <p>",
"    Hypothermia may contribute to metabolic disorders such as hypoglycemia or acidosis. In extremely premature infants of less than 26 weeks gestation, hypothermia is associated with increased mortality and, in survivors, pulmonary insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature infants are at greatest risk for hypothermia immediately after birth in the delivery room. This was best illustrated in a multicenter study from the NICHD Neonatal Research Network that reviewed the body temperature of 5277 LBW infants (mean birth weight 1036 g and mean gestational age 28 weeks) when they were admitted to the NICU between 2002 and 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/9\">",
"     9",
"    </a>",
"    ]. The following distribution of admission temperatures was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 35&deg;C &ndash; 14 percent",
"     </li>",
"     <li>",
"      35 to 35.9&deg;C &ndash; 33 percent",
"     </li>",
"     <li>",
"      36 to 36.9&deg;C &ndash; 42 percent",
"     </li>",
"     <li>",
"      Greater than 37&deg;C &ndash; 11 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multivariate analysis, admission temperature was inversely related to mortality and late-onset sepsis. In contrast, higher admission temperatures were associated with increased birth weights with admission temperature rising 0.04&deg;C for each 100 g increase in birth weight. In intubated patients, the increase in temperature was 0.13&deg;C for each 100 g increase in birth weight. There was no association between admission temperature and the risk of necrotizing enterocolitis, severe intracranial hemorrhage (eg, grade III or IV), or duration of mechanical ventilation.",
"   </p>",
"   <p>",
"    In a population-based cohort study of VLBW infants born in California NICUs in 2006 and 2007, 56 percent of infants were hypothermic (temperature &lt;36.5&deg;C based on the World Health organization [WHO] classification of hypothermia) at the time of admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/10\">",
"     10",
"    </a>",
"    ]. Hypothermia was more likely with decreasing birth weight, cesarean delivery, and low Apgar score. Decreased risk of hypothermia was associated with spontaneous labor, prolonged rupture of membranes, and antenatal steroid administration. There was an increase in mortality with moderate (temperature &lt;36&deg;C) and severe (temperature &lt;32&deg;C) hypothermia, and an increase risk of intraventricular hemorrhage in infants with moderate hypothermia.",
"   </p>",
"   <p>",
"    Standard care in the delivery room to prevent hypothermia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintaining the delivery room temperature at a minimum of 26&ordm;C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drying the baby thoroughly immediately after birth",
"     </li>",
"     <li>",
"      Removal of any wet blankets",
"     </li>",
"     <li>",
"      Use of prewarmed radiant heaters if resuscitation is necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In premature infants, additional interventions have been used to reduce hypothermia that either are barriers to heat loss (ie,",
"    <span class=\"nowrap\">",
"     polyethylene/polyurethane",
"    </span>",
"    body wrap or bags, and polyethylene or stockinet caps) or are external heat sources (ie, skin to skin care and transwarmer mattress) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/12-16\">",
"     12-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of the literature reported led to less hypothermia and higher temperatures on admission to NICUs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/17\">",
"     17",
"    </a>",
"    ]. In one of the largest trials (88 infants with a GA &lt;28 weeks) included in the systematic review, infants randomized to placement within a polyurethane bag immediately after birth were less likely than control infants to be hypothermic (&lt;36.4&deg;C) on admission to the NICU (44 versus 70 percent) and had higher mean temperature (36.5&deg;C versus 36&deg;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/13\">",
"     13",
"    </a>",
"    ]. In a subsequent trial, the use of polyethylene caps in the delivery room resulted in similar temperatures on admission to the NICU as body wraps (36.1&deg;C versus 35.8&deg;C), both of which were significantly higher than temperatures in control infants who received no additional intervention than drying in the delivery room (35.3&deg;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent study of 102 preterm infants with gestational age &lt;32 weeks, the mean admission temperature was greater in preterm infants who were transported to the NICU using a trans-warmer mattress compared with controls infants (36.2&plusmn;0.8 versus 35.7&plusmn;0.8&deg;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, the risk of hypothermia was lower in patients transported by trans-warmer mattress.",
"   </p>",
"   <p>",
"    In a small trial of 39 preterm infants (gestational age &le;28 weeks), the mean temperature was higher in infants assigned to thermal warming mattresses compared with those treated with polyethylene wrap as interventions to avoid hypothermia (36.5&plusmn;0.67 versus 36.1&plusmn;0.66&deg;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/19\">",
"     19",
"    </a>",
"    ]. However, further investigation is needed before a specific intervention to prevent hypothermia can be recommended.",
"   </p>",
"   <p>",
"    Once in the NICU, premature infants should be cared for in an incubator or radiant warmer to avoid hypothermia.",
"   </p>",
"   <p>",
"    In developing countries, skin-enhancing emollients (eg, Aquaphor ointment or sunflower seed oil) provide a skin barrier therapy, which reduces transepidermal loss of heat and water, the risk of nosocomial infection, and improves survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Respiratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory complications of prematurity include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory distress syndrome (RDS) is caused by surfactant deficiency. The incidence and severity of RDS increase with decreasing gestational age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchopulmonary dysplasia, also known as chronic lung disease, is a late respiratory complication that commonly occurs in VLBW infants. It is defined as oxygen dependency at 36 weeks postmenstrual age (PMA). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18793?source=see_link\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Apnea of prematurity occurs in approximately 25 percent of preterm infants. The incidence of this disorder increases with decreasing gestational age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43223?source=see_link\">",
"       \"Management of apnea of prematurity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Premature infants should have continuous monitoring of heart rate and respiration beginning immediately after birth. Oxygenation also should be monitored to avoid the consequences of hypoxia or hyperoxia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29656?source=see_link\">",
"     \"Oxygen monitoring and therapy in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiovascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications in the premature infant include patent ductus arteriosus (PDA) and systemic hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Patent ductus arteriosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic PDA is common in premature neonates, occurring in about 30 percent of VLBW infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/7\">",
"     7",
"    </a>",
"    ]. The PDA shunts blood flow from left-to-right resulting in increased flow through the pulmonary circulation and decreased perfusion of the systemic circulation. The physiologic consequences of the PDA depend upon the size of the shunt and the response of the heart and lungs to the shunt. Significant shunting may present with a variety of symptoms including apnea, respiratory distress, or heart failure. PDA in the premature infant is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although low blood pressure (BP), without evidence of shock, is commonly observed in neonates, especially in ELBW infants, several issues remain unresolved including: do infants with low BP without shock have worse outcomes, is intervention for such low BP beneficial, and if intervention is used, what BP threshold should be used and what is the optimal choice of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]? Despite this uncertainty, interventions are commonly used to increase low BP especially in ELBW infants because of concerns that untreated low BP leads to low systemic blood flow that results in significant morbidity (eg, intraventricular hemorrhage [IVH]) and mortality in preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the effects of low BP and its treatment are limited and inconsistent. As an example, studies that examine the effect of low BP on neurodevelopmental outcome have conflicting results as demonstrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study of infants born between 23 and 25 weeks gestation, survivors who had low BP (defined as &ge;3 measurements of mean arterial blood pressure &le;25 mmHg in the first 72 hours of life) compared to those with normal BP were more likely have poor neurodevelopment outcome at 18 to 22 months postmenstrual age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/27\">",
"       27",
"      </a>",
"      ]. The hypotensive group, regardless of whether they were treated or not, had increased rates of cerebral palsy and deafness, and lower scores on the Bayley scales infant development.",
"     </li>",
"     <li>",
"      In contrast, a prospective study of 84 infants with a gestational age &le;30 weeks found no association between hypotension and the risk of brain lesions detected by cranial ultrasound between 5 and 10 days of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/28\">",
"       28",
"      </a>",
"      ]. However, limited monitoring during the first 12 hours of life, lack of an early ultrasound, and the large (70 percent) use of interventions (volume or pressors) may have affected these observations.",
"     </li>",
"     <li>",
"      In a report from the ELGAN (extremely low gestational age newborn) study of 945 infants with a gestational age &lt;28 weeks, logistic regression analysis adjusted for potential confounding factors demonstrated no association between lowest recorded BP and developmental outcome at 24 months corrected age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/29\">",
"       29",
"      </a>",
"      ]. However, intermittent measurements of BP and not evaluating the duration of low BP may have affected these observations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contributing factors to low BP may include perinatal asphyxia, hemodynamically significant PDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/30\">",
"     30",
"    </a>",
"    ], infection, hypoxia, immaturity of the receptors and systems that regulate blood pressure, and relative adrenal insufficiency.",
"   </p>",
"   <p>",
"    Management options used to increase low BP include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume expansion &ndash; Both crystalloid (eg, normal saline) and colloid (eg, fresh frozen plasma and albumin) solutions are used for volume expansion in the treatment of hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/31\">",
"       31",
"      </a>",
"      ]. Based upon a meta-analysis, there is no evidence that early volume expansion with either crystalloid or colloid solution is beneficial in preterm infants who do not have cardiovascular compromise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inotropic therapy &ndash; In many cases, volume expansion alone is insufficient to maintain adequate blood pressure levels. In these patients, inotropic therapy can be used.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=see_link\">",
"       Dopamine",
"      </a>",
"      infusion is generally used as the initial agent as it is more effective than",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/48/25348?source=see_link\">",
"       dobutamine",
"      </a>",
"      in the short-term treatment of systemic hypotension in preterm infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. If dopamine alone is ineffective, dobutamine and epinephrine may be added. More than half of VLBW infants initially treated with inotropic therapy will either fail to respond or become dependent on medium to high doses of inotropic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic glucocorticoid therapy &ndash; Several clinical studies report a beneficial effect of systemic glucocorticoid therapy in either patients with refractory hypotension or those who required high dose inotropic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/35-38\">",
"       35-38",
"      </a>",
"      ]. In a systematic review, two trials that evaluated the effect of corticosteroid therapy in preterm infant with hypotension refractory to volume expansion and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      therapy demonstrated a reduction in persistent hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/38\">",
"       38",
"      </a>",
"      ]. However, there was no beneficial effect on short or medium-term morbidity or mortality from corticosteroid treatment, the number of patients included in the analysis was small, and the long-term effects of corticosteroid therapy are unknown [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/38\">",
"       38",
"      </a>",
"      ]. &nbsp;",
"      <br/>",
"      <br/>",
"      In addition, a secondary analysis of a randomized trial of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      to prevent bronchopulmonary dysplasia reported low cortisol values at baseline (between 12 and 48 hours after delivery), and at days five and seven of life were not associated with increased morbidity or mortality rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. The use of vasopressor therapy was lower for infants with lower cortisol values at baseline. In contrast, severe IVH was more frequent in infants with cortisol values in the upper quartile at baseline. In addition, infants with baseline values that were greater than the 90 percentile had a higher risk of death, severe IVH, periventricular leukomalacia, gastrointestinal perforation, and severe retinopathy of prematurity than infants in the middle quartiles. Of note, there was no predictable change in cortisol levels based upon treatment with hydrocortisone or placebo. Patients who remain in the upper quartile at days 5 to 7 regardless of treatment group were more likely to have an adverse outcome, especially severe IVH.",
"      <br/>",
"      <br/>",
"      These findings underscore the uncertainty of whether or not systemic steroids should be used in settings of hypotension, because it is not clear if they are of benefit, and there is a possibility of adverse effects such as intestinal perforation and long-term poor neurodevelopment outcome (eg, cerebral palsy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, it is unclear what a normal cortisol level should be in premature infants, because it remains unknown what the normal variation of serum cortisol levels are based upon gestational age and what the impact of different levels of stress is upon the response of the premature",
"      <span class=\"nowrap\">",
"       hypothalamic/pituitary-adrenal",
"      </span>",
"      axis and subsequent cortisol values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3353?source=see_link\">",
"       \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Despite these concerns, systemic glucocorticoids are used not uncommonly to treat refractory hypotension. This was illustrated in a study of 1401 VLBW infants from the California Perinatal Quality Care Collaborative (CPQCC) group from 2002 to 2003 that reported systemic steroids were used to treat hypotension in about 13 percent of the group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although further studies are needed to determine whether and what interventions should be performed for low BP in preterm infants, it is challenging to conduct randomized controlled trials to address these issues because of difficulties in enrolling eligible patients in sufficient numbers to answer the clinically relevant questions: does treatment of traditionally considered low BP improve outcome, and if so, what is the optimal intervention and what are the indications for administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intraventricular hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular hemorrhage (IVH) usually occurs in the fragile germinal matrix and increases in frequency with decreasing birth weight. The incidence of severe IVH (Grades III and IV) is about 12 to 15 percent in VLBW [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General preventive measures include prompt and appropriate resuscitation. In addition, efforts should be made to avoid hemodynamic instability and conditions that impair cerebral autoregulation (eg, hypoxia, hypercarbia, hyperoxia, and hypocarbia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Glucose abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders in glucose supply or metabolism can result in hypoglycemia or hyperglycemia. Blood glucose concentration should be monitored routinely starting within one to two hours after birth and continued until feedings are well established and glucose values have normalized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link\">",
"     \"Neonatal hyperglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Necrotizing enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing enterocolitis (NEC) occurs in 2 to 10 percent of VLBW infants. NEC is associated with an increase in mortality. Survivors are at increased risk for growth delay and neurodevelopmental disabilities. In addition, 10 percent of preterm infants with NEC will have long-term gastrointestinal difficulties with persistent loose stools or frequent bowel movements.",
"   </p>",
"   <p>",
"    The clinical features and treatment of NEC are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35928?source=see_link\">",
"     \"Management of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset sepsis, defined as occurring after three days of age, is a common complication among premature infants. As an example, in a study from the NICHD Neonatal Research Network, one or more episodes of sepsis (defined as a positive blood culture associated with clinical signs suggestive of infection) occurred in 21 percent of VLBW infants who survived more than three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/44\">",
"     44",
"    </a>",
"    ]. Gram-positive organisms caused infection in 70 percent of cases, and coagulase-negative staphylococcus accounted for 48 percent. Patients who developed late-onset sepsis were more likely to die than those who were uninfected, and survivors had longer hospital stays (79 versus 60 days). Other complications associated with an increased risk of infection included prolonged intubation, bronchopulmonary dysplasia, prolonged intravascular access, PDA, and NEC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=see_link&amp;anchor=H11#H11\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, fungal infection, primarily candidiasis, accounted for 9 percent of cases of late-onset sepsis and was associated with a high mortality rate of 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal sepsis is associated with increased likelihood of poor neurodevelopmental outcome and growth impairment. In another report from the NICHD Neonatal Research Network, ELBW survivors who had one episode of neonatal infection compared to those who were uninfected were more likely to have adverse neurodevelopmental outcome and poor growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31992/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Retinopathy of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy of prematurity (ROP) is a developmental vascular proliferative disorder that occurs in the incompletely vascularized retina of premature infants. The incidence and severity of ROP increase with decreasing gestational age or birth weight. The condition typically begins at about 34 weeks postmenstrual age (PMA), although it may be seen as early as 30 to 32 weeks. ROP advances irregularly until 40 to 45 weeks PMA and resolves spontaneously in the majority of infants. However, patients with severe untreated ROP are at increased risk for poor ocular outcome with vision impairment.",
"   </p>",
"   <p>",
"    Retinopathy of prematurity and its management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=see_link\">",
"     \"Retinopathy of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/62/8163?source=see_link\">",
"       \"Patient information: What to expect in the NICU (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/28/19905?source=see_link\">",
"       \"Patient information: Retinopathy of prematurity (ROP) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/38/2659?source=see_link\">",
"       \"Patient information: When a baby is born premature (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity is defined as a birth that occurs before 37 completed weeks (less than 259 days) of gestation. It is associated with approximately one-third of all infant deaths in the United States and accounts for approximately 45 percent of children with cerebral palsy, 35 percent of children with vision impairment, and 25 percent of children with cognitive or hearing impairment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of prematurity are the underlying reasons for the higher rate of infant mortality and morbidity in these infants compared to full-term infants. The risk of complications increases with decreasing gestational age and birth weight. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications are divided into short-term complications (eg, respiratory and cardiovascular complications), which occur in the neonatal period, and long-term sequelae (eg, neurodevelopmental disabilities such as cerebral palsy). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=see_link\">",
"       \"Long-term complications of the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The short-term complications most commonly seen are hypothermia, respiratory abnormalities, cardiovascular abnormalities, intracranial hemorrhage, hypoglycemia, necrotizing enterocolitis, infection, and retinopathy of prematurity. The presence of one or more of these complications increases the risk of death and in survivors, increases the likelihood of long-term complications. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/1\">",
"      Eichenwald EC, Stark AR. Management and outcomes of very low birth weight. N Engl J Med 2008; 358:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/2\">",
"      Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/3\">",
"      Costeloe KL, Hennessy EM, Haider S, et al. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ 2012; 345:e7976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/4\">",
"      Altman M, Vanp&eacute;e M, Cnattingius S, Norman M. Neonatal morbidity in moderately preterm infants: a Swedish national population-based study. J Pediatr 2011; 158:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/5\">",
"      Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/6\">",
"      Niermeyer S, Kattwinkel J, Van Reempts P, et al. International Guidelines for Neonatal Resuscitation: An excerpt from the Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: International Consensus on Science. Contributors and Reviewers for the Neonatal Resuscitation Guidelines. Pediatrics 2000; 106:E29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/7\">",
"      Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196:147.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/8\">",
"      Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/9\">",
"      Laptook AR, Salhab W, Bhaskar B, Neonatal Research Network. Admission temperature of low birth weight infants: predictors and associated morbidities. Pediatrics 2007; 119:e643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/10\">",
"      Miller SS, Lee HC, Gould JB. Hypothermia in very low birth weight infants: distribution, risk factors and outcomes. J Perinatol 2011; 31 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/11\">",
"      Jia YS, Lin ZL, Lv H, et al. Effect of delivery room temperature on the admission temperature of premature infants: a randomized controlled trial. J Perinatol 2013; 33:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/12\">",
"      McCall EM, Alderdice FA, Halliday HL, et al. Interventions to prevent hypothermia at birth in preterm and/or low birthweight infants. Cochrane Database Syst Rev 2008; :CD004210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/13\">",
"      Knobel RB, Wimmer JE Jr, Holbert D. Heat loss prevention for preterm infants in the delivery room. J Perinatol 2005; 25:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/14\">",
"      Cramer K, Wiebe N, Hartling L, et al. Heat loss prevention: a systematic review of occlusive skin wrap for premature neonates. J Perinatol 2005; 25:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/15\">",
"      Ibrahim CP, Yoxall CW. Use of self-heating gel mattresses eliminates admission hypothermia in infants born below 28 weeks gestation. Eur J Pediatr 2010; 169:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/16\">",
"      Trevisanuto D, Doglioni N, Cavallin F, et al. Heat loss prevention in very preterm infants in delivery rooms: a prospective, randomized, controlled trial of polyethylene caps. J Pediatr 2010; 156:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/17\">",
"      McCall EM, Alderdice F, Halliday HL, et al. Interventions to prevent hypothermia at birth in preterm and/or low birthweight infants. Cochrane Database Syst Rev 2010; :CD004210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/18\">",
"      Chawla S, Amaram A, Gopal SP, Natarajan G. Safety and efficacy of Trans-warmer mattress for preterm neonates: results of a randomized controlled trial. J Perinatol 2011; 31:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/19\">",
"      Simon P, Dannaway D, Bright B, et al. Thermal defense of extremely low gestational age newborns during resuscitation: exothermic mattresses vs polyethylene wrap. J Perinatol 2011; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/20\">",
"      Darmstadt GL, Saha SK, Ahmed AS, et al. Effect of skin barrier therapy on neonatal mortality rates in preterm infants in Bangladesh: a randomized, controlled, clinical trial. Pediatrics 2008; 121:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/21\">",
"      Barrington KJ. Low blood pressure in extremely preterm infants: does treatment affect outcome? Arch Dis Child Fetal Neonatal Ed 2011; 96:F316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/22\">",
"      Batton BJ, Li L, Newman NS, et al. Feasibility study of early blood pressure management in extremely preterm infants. J Pediatr 2012; 161:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/23\">",
"      Vain NE, Barrington KJ. Feasibility of evaluating treatment of early hypotension in extremely low birth weight infants. J Pediatr 2012; 161:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/24\">",
"      Seri I, Noori S. Diagnosis and treatment of neonatal hypotension outside the transitional period. Early Hum Dev 2005; 81:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/25\">",
"      Osborn DA, Evans N, Kluckow M, et al. Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. Pediatrics 2007; 120:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/26\">",
"      Miletin J, Dempsey EM. Low superior vena cava flow on day 1 and adverse outcome in the very low birthweight infant. Arch Dis Child Fetal Neonatal Ed 2008; 93:F368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/27\">",
"      Batton B, Zhu X, Fanaroff J, et al. Blood pressure, anti-hypotensive therapy, and neurodevelopment in extremely preterm infants. J Pediatr 2009; 154:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/28\">",
"      Limperopoulos C, Bassan H, Kalish LA, et al. Current definitions of hypotension do not predict abnormal cranial ultrasound findings in preterm infants. Pediatrics 2007; 120:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/29\">",
"      Logan JW, O'Shea TM, Allred EN, et al. Early postnatal hypotension and developmental delay at 24 months of age among extremely low gestational age newborns. Arch Dis Child Fetal Neonatal Ed 2011; 96:F321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/30\">",
"      Sarkar S, Dechert R, Schumacher RE, Donn SM. Is refractory hypotension in preterm infants a manifestation of early ductal shunting? J Perinatol 2007; 27:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/31\">",
"      Lynch SK, Mullett MD, Graeber JE, Polak MJ. A comparison of albumin-bolus therapy versus normal saline-bolus therapy for hypotension in neonates. J Perinatol 2008; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/32\">",
"      Osborn DA, Evans N. Early volume expansion for prevention of morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2001; :CD002055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/33\">",
"      Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database Syst Rev 2003; :CD001242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/34\">",
"      Sassano-Higgins S, Friedlich P, Seri I. A meta-analysis of dopamine use in hypotensive preterm infants: blood pressure and cerebral hemodynamics. J Perinatol 2011; 31:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/35\">",
"      Ng PC, Lee CH, Bnur FL, et al. A double-blind, randomized, controlled study of a \"stress dose\" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 2006; 117:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/36\">",
"      Noori S, Friedlich P, Wong P, et al. Hemodynamic changes after low-dosage hydrocortisone administration in vasopressor-treated preterm and term neonates. Pediatrics 2006; 118:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/37\">",
"      Baker CF, Barks JD, Engmann C, et al. Hydrocortisone administration for the treatment of refractory hypotension in critically ill newborns. J Perinatol 2008; 28:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/38\">",
"      Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in preterm infants. Cochrane Database Syst Rev 2011; :CD003662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/39\">",
"      Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/40\">",
"      Aucott SW, Watterberg KL, Shaffer ML, et al. Do cortisol concentrations predict short-term outcomes in extremely low birth weight infants? Pediatrics 2008; 122:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/41\">",
"      Hallman M, Peltoniemi O, Saarela T. Early neonatal hydrocortisone: study rather than treat. Pediatrics 2006; 118:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/42\">",
"      Ng PC. Is there a \"normal\" range of serum cortisol concentration for preterm infants? Pediatrics 2008; 122:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/43\">",
"      Finer NN, Powers RJ, Ou CH, et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics 2006; 117:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/44\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/45\">",
"      Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31992/abstract/46\">",
"      Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292:2357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4965 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31992=[""].join("\n");
var outline_f31_15_31992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial stabilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Respiratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiovascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intraventricular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Glucose abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Necrotizing enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/8/1163\" title=\"table 1\">",
"      Definition of prematurity based on birth weights",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/59/11197\" title=\"table 2\">",
"      Birth weight by gestational age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=related_link\">",
"      Long-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35928?source=related_link\">",
"      Management of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/28/19905?source=related_link\">",
"      Patient information: Retinopathy of prematurity (ROP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/38/2659?source=related_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3353?source=related_link\">",
"      Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31993="Unipolar depression in adults: Treatment with second-generation antipsychotics";
var content_f31_15_31993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults: Treatment with second-generation antipsychotics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31993/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31993/contributors\">",
"     Craig Nelson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31993/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31993/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/15/31993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21954874\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation antipsychotics are indicated for unipolar major depression, as well as other psychiatric disorders such as schizophrenia and bipolar disorder. For major depression, atypical antipsychotics are used adjunctively for nonpsychotic patients who respond insufficiently to antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Second-generation antipsychotics in combination with an antidepressant are also effective for psychotic depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/3\">",
"     3",
"    </a>",
"    ], and the atypical antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    is effective as monotherapy for nonpsychotic depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/4\">",
"     4",
"    </a>",
"    ]. The efficacy of atypical antipsychotics for major depression is hypothesized to be the result of their serotonergic, noradrenergic, and dopaminergic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/5-11\">",
"     5-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First-generation antipsychotics have also been used to treat depression, initially as monotherapy and subsequently as adjunctive treatment with an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Randomized trials found that for nonpsychotic depression, first-generation antipsychotic monotherapy was superior to placebo and either comparable or superior to an antidepressant. However, the use of first-generation antipsychotics for depression has declined because of the risk of tardive dyskinesia, which is greater for first-generation than second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This topic reviews the use of second-generation antipsychotics for treating unipolar major depression. The initial treatment of depression, treatment of resistant depression, clinical features and diagnosis of depression, and the pharmacology of second-generation antipsychotics are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493149\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An episode of major depressive disorder (unipolar major depression) is defined in the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) as a period lasting at least two weeks, with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, decreased energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/15\">",
"     15",
"    </a>",
"    ]. Additional information about the clinical features and diagnosis of major depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493815\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In unipolar major depression, second-generation antipsychotics are indicated for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpsychotic depression that does not respond sufficiently to antidepressant monotherapy &ndash; the antipsychotic is generally added to the same antidepressant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psychotic depression &ndash; the antipsychotic is started concurrently with an antidepressant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the second-generation antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    may be efficacious as monotherapy for unipolar, nonpsychotic major depression, and thus an option when switching from an ineffective treatment regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21954769\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE TREATMENT FOR NONPSYCHOTIC DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive medications are commonly used to treat unipolar nonpsychotic depression, because many patients respond insufficiently to antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, an open-label study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    in 3671 patients with major depression found that remission occurred in only 37 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among available adjunctive medications, many authorities and clinicians choose a second-generation antipsychotic. In a study of a pharmacy database that included nearly 250,000 depressed patients receiving an antidepressant, 7 percent also received an atypical antipsychotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/1\">",
"     1",
"    </a>",
"    ]. Other choices for augmentation include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/23\">",
"     23",
"    </a>",
"    ] and triiodothyronine (T",
"    <sub>",
"     3",
"    </sub>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/24\">",
"     24",
"    </a>",
"    ]. Additional information about augmenting an antidepressant in treatment resistant depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of resistant depression in adults\", section on 'Augmentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430764\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of augmenting an antidepressant with a second-generation antipsychotic is established for acute treatment of major depression but not maintenance treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2,25-27\">",
"     2,25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550095\">",
"    <span class=\"h3\">",
"     Acute phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of second-generation antipsychotics for acute treatment of depression is based upon a meta-analysis of 16 randomized trials that compared the efficacy of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    with placebo in 3480 patients with major depressive disorder who failed monotherapy with an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment resistance was determined either by history or prospectively. The study drug was added to the original, ongoing antidepressant in 14 of the trials; in 2 trials, the study drug and a new antidepressant were started concurrently. The trials generally lasted either six or eight weeks. Key findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission occurred in significantly more patients who received an antipsychotic than in than in those who received a placebo (31 versus 17 percent)",
"     </li>",
"     <li>",
"      Response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received an antipsychotic (44 versus 30 percent)",
"     </li>",
"     <li>",
"      Neither remission nor response rates differed significantly among the four antipsychotics",
"     </li>",
"     <li>",
"      Response was comparable for patients who failed antidepressant monotherapy by history or prospective treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differences in efficacy between adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    have not been demonstrated, but no head-to-head randomized trials have been conducted. In addition, it is possible that secondary clinical effects may differentially affect the utility of adjunctive antipsychotics for treating major depression. As an example, quetiapine is a sedating atypical antipsychotic and is useful for insomnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"     28",
"    </a>",
"    ]. Olanzapine causes the most weight gain, which may help patients with anorexia and excessive weight loss.",
"   </p>",
"   <p>",
"    It is reasonable to use an adjunctive antipsychotic with any antidepressant. In randomized trials, the antipsychotic was usually added to a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement of depressive symptoms with adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    largely occurred within the first two weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. Thus, we suggest that clinicians wait at least this long before determining whether the drug is useful. Patients who improve less than 25 percent from baseline by week four of treatment are unlikely to respond further with longer treatment.",
"   </p>",
"   <p>",
"    No randomized, placebo controlled trials have evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/59/35767?source=see_link\">",
"     iloperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/1/15383?source=see_link\">",
"     lurasidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    as adjunctive treatment for patients with unipolar, nonpsychotic major depression that has failed antidepressant monotherapy. However, these drugs are reasonable alternatives for patients who have failed or cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    should be avoided because it can cause agranulocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550103\">",
"    <span class=\"h4\">",
"     Minimal response compared with partial response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive second-generation antipsychotics may be effective for patients with either a minimal response to antidepressant monotherapy or a partial response. Although it is commonly thought that augmentation is more useful to increase the improvement achieved in partial responders than in minimal responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], this is not established.",
"   </p>",
"   <p>",
"    A pooled analysis of three randomized trials compared adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    (2 to 20 mg per day) with placebo in patients with unipolar major depression who were initially treated eight weeks with open-label antidepressant monotherapy, and had either a minimal response (improvement from baseline on the depression rating scale &lt;25 percent) or partial response (improvement of 25 to 49 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/35\">",
"     35",
"    </a>",
"    ]. The primary findings after six weeks of adjunctive treatment were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 746 patients with an initial minimal response, remission occurred in significantly more patients who received adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      than placebo (24 versus 12 percent).",
"     </li>",
"     <li>",
"      Among 292 patients with an initial partial response, remission was larger for adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      than placebo (41 versus 31 percent), but the difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539368\">",
"    <span class=\"h4\">",
"     Comparisons with other adjunctive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have compared second-generation antipsychotics with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , triiodothyronine (T",
"    <sub>",
"     3",
"    </sub>",
"    ), or a second antidepressant as adjunctive treatment for major depression that has failed antidepressant monotherapy.",
"   </p>",
"   <p>",
"    The 16 randomized trials (3480 patients with major depression) of adjunctive second-generation antipsychotics represent the most rigorous body of evidence for any type of adjunctive treatment in depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"     2",
"    </a>",
"    ]. By contrast, the 10 randomized trials of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    included only 269 depressed patients, many of whom would not meet current criteria for treatment resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/23\">",
"     23",
"    </a>",
"    ]. Comparisons between lithium and other adjunctive agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17192?source=see_link&amp;anchor=H2757307#H2757307\">",
"     \"Unipolar depression in adults: Treatment with lithium\", section on 'Compared with other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550119\">",
"    <span class=\"h3\">",
"     Maintenance phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression who have failed multiple treatment regimens and then responded to an adjunctive second-generation antipsychotic that is well-tolerated, it is reasonable to continue the antipsychotic to prevent relapse. However, one randomized trial found no benefit in this context.",
"   </p>",
"   <p>",
"    In the randomized trial, patients with major depression unresponsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    monotherapy (20 to 60 mg per day) were given open-label adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (0.25 to 2 mg per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/25\">",
"     25",
"    </a>",
"    ]. The 241 patients who remitted or were much improved were treated for six months with citalopram plus risperidone or citalopram plus placebo. Neither relapse rates nor median time to relapse differed significantly between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432190\">",
"    <span class=\"h2\">",
"     Safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of adjunctive second-generation antipsychotics need to be weighed against safety issues that include the metabolic syndrome, and the less common but serious problems of tardive dyskinesia and neuroleptic malignant syndrome (NMS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9371665\">",
"    <span class=\"h3\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain, diabetes, and hyperlipidemia are elements of the metabolic syndrome that can occur with second-generation antipsychotics, although the frequency of these problems appears to vary depending upon the specific drug that is used. However, rates of the metabolic syndrome during randomized trials of adjunctive atypical antipsychotics in patients with unipolar major depression have not been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28,36,37\">",
"     28,36,37",
"    </a>",
"    ]. Metabolic side effects of antipsychotics are discussed separately in the context of schizophrenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link&amp;anchor=H28219059#H28219059\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\", section on 'Metabolic side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244492\">",
"    <span class=\"h3\">",
"     Tardive dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tardive dyskinesia is less common with second-generation antipsychotics than first-generation antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/14\">",
"     14",
"    </a>",
"    ], it is still a concern because tardive dyskinesia may be irreversible, depressed patients may be at greater risk, and tardive dyskinesia is not associated with most other augmentation options. The risk of tardive dyskinesia with second-generation antipsychotics in unipolar major depression is not well established: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12-week, randomized trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      in 259 patients with unipolar psychotic depression found that tardive dyskinesia occurred in 8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/3\">",
"       3",
"      </a>",
"      ]. However, it appears that this rate may have reflected prior antipsychotic use and very sensitive criteria rather than new cases of tardive dyskinesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No new cases of tardive dyskinesia were found in a 76-week open-label study of adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      in 560 patients with unipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 52-week, open-label study of adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      in 1002 patients with unipolar major depression found four cases of tardive dyskinesia for an annualized rate was 0.7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/40\">",
"       40",
"      </a>",
"      ]. Without a control group, this rate may overestimate the rate of tardive dyskinesia due to drug.",
"     </li>",
"     <li>",
"      A 52-week, randomized monotherapy maintenance trial in 391 patients with unipolar major depression assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      XR did not find evidence of tardive dyskinesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/41\">",
"       41",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Rates of tardive dyskinesia have not been reported for adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      in unipolar major depression during long term treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the risk of tardive dyskinesia with second-generation antipsychotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link&amp;anchor=H8#H8\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\", section on 'Second-generation antipsychotic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540929\">",
"    <span class=\"h3\">",
"     Neuroleptic malignant syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuroleptic malignant syndrome (NMS) can occur with second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, rates of NMS for atypical antipsychotics are not established in part because of the large sample required to reasonably estimate the rate of a rarely occurring event. In addition, bias may exist in that an atypical agent is likely to be given to patients who require an antipsychotic and have a prior history of NMS. NMS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86138377\">",
"    <span class=\"h3\">",
"     Suicidal thinking and behavior in young adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second-generation antipsychotics carry a class warning (product information in the United States) about a possible increased risk of suicidal ideation or suicide attempt in patients under the age of 25 years. However, this risk was not established in trials of atypical antipsychotics, and this risk may be reduced if adjunctive treatment is begun six to eight weeks after the patient has received an antidepressant. Second-generation antipsychotics may potentially be useful for treating suicidal ideation as well as symptoms such as agitation, anxiety, and insomnia, which may aggravate suicidal thinking and behavior.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A preplanned, pooled analysis of two randomized trials examined suicidal ideation in 936 patients (age 18 to 65 years) with major depression who did not respond sufficiently to antidepressant monotherapy and subsequently received adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (150 mg or 300 mg per day) or placebo for six weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"       28",
"      </a>",
"      ]. Treatment-emergent suicidal ideation occurred in more patients who received placebo than in those who received quetiapine (2.6 versus 0.6 and 1.0 percent; not tested statistically). &nbsp;",
"     </li>",
"     <li>",
"      A post hoc, pooled analysis of two randomized trials examined suicidal ideation in 702 patients (age &gt;25 years) with major depression who did not respond sufficiently to antidepressant monotherapy and subsequently received adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      (2 to 20 mg per day) or placebo for six weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/44\">",
"       44",
"      </a>",
"      ]. Treatment-emergent suicidal ideation occurred in significantly more patients who received placebo than aripiprazole (relative risk 0.14, 95% CI 0.03-0.60). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, treatment emergent suicidality with adjunctive second-generation antipsychotics in unipolar major depression has not been well studied in patients who are under 25 years of age and at greatest risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540872\">",
"    <span class=\"h2\">",
"     Dose, side effects, and drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of an adjunctive second-generation antipsychotic for nonpsychotic unipolar major depression is often lower than the dose used for schizophrenia or bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/29,30,45,46\">",
"     29,30,45,46",
"    </a>",
"    ]. Short-term use of adjunctive atypical antipsychotics for depression is usually well tolerated; however, randomized trials found that adverse effects led patients to discontinue treatment at significantly greater rates than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the benefits of adjunctive treatment need to be weighed against adverse effects that include weight gain, sedation, and extrapyramidal symptoms. In addition, serum concentrations of adjunctive antipsychotics may be affected by drug-drug interactions with an antidepressant; however, the antipsychotics appear to have minimal effects on the clearance of other drugs. Specific interactions of second-generation antipsychotics with antidepressants may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions.",
"   </p>",
"   <p>",
"    The methods used in randomized trials of adjunctive second-generation antipsychotics for major depression may suggest the need for doses that are higher than necessary. Clinicians may thus find that doses at the lower end of the range that was used in the trials are effective in many patients; higher doses can be reserved for patients with an inadequate response to the antipsychotic or severely ill patients requiring an especially fast response. Therapeutic serum concentrations have not been established for adjunctive second-generation antipsychotics in major depression and are not used to guide dosing.",
"   </p>",
"   <p>",
"    Side effects were examined in a meta-analysis of 16 randomized trials involving adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    in 3480 patients with major depression who failed monotherapy with an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"     2",
"    </a>",
"    ]. Discontinuation of treatment because of adverse effects was significantly higher in patients who received an adjunctive antipsychotic compared with placebo (9 versus 2 percent). Treatment of approximately 17 patients with the antipsychotic caused discontinuation in one additional patient that would not have occurred with placebo (number needed to harm of 17, which is generally regarded as not clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/47\">",
"     47",
"    </a>",
"    ]). The rate of discontinuation from treatment because of side effects did not differ significantly among the four atypical antipsychotics.",
"   </p>",
"   <p>",
"    <strong>",
"     Weight gain",
"    </strong>",
"    was common during short-term randomized trials of adjunctive second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28,36,37\">",
"     28,36,37",
"    </a>",
"    ], especially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    . A pooled analysis of two adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    trials suggested that weight gain may be greater during combination treatment with an antidepressant in unipolar major depression, compared with weight gain reported in monotherapy trials in schizophrenia or bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term treatment may cause additional weight gain. In a randomized trial (N = 386), adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    caused weight gain &ge; 7 percent of body weight from baseline to end point of study phase in 3 percent of the patients during the initial 4 to 6-week open-label phase, and in another 8 percent of patients during the 24-week double-blind phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/25\">",
"     25",
"    </a>",
"    ]. It is worth mentioning that major depression may cause weight loss; thus, weight gain may be desirable in some patients.",
"   </p>",
"   <p>",
"    Additional information about the side effects of second-generation antipsychotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432220\">",
"    <span class=\"h3\">",
"     Aripiprazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    for unipolar major depression ranges from 5 to 20 mg per day. The most common side effect is akathisia.",
"   </p>",
"   <p>",
"    The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    was established in three randomized trials that lasted six weeks; 547 patients with major depression received active drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/29,31,49\">",
"     29,31,49",
"    </a>",
"    ]. Aripiprazole was started at 5 mg and increased each week by increments of 5 mg per day as clinically indicated, to a maximum of 20 mg per day. The mean final dose was 11 mg per day. (Although a decrease to 2 mg per day was permitted, a subsequent randomized trial found that adjunctive aripiprazole 2 mg per day was not beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/50\">",
"     50",
"    </a>",
"    ].)",
"   </p>",
"   <p>",
"    In a pooled analysis of two randomized trials (N = 737), side effects that occurred in significantly more patients who received adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    than in those who received placebo included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Akathisia (25 versus 4 percent of patients)",
"     </li>",
"     <li>",
"      Restlessness (12 versus 2 percent)",
"     </li>",
"     <li>",
"      Insomnia (8 versus 3 percent)",
"     </li>",
"     <li>",
"      Blurred vision (6 versus 1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mean weight gain was also significantly greater with adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    than placebo (1.7 versus 0.4 kg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432348\">",
"    <span class=\"h3\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    for unipolar major depression ranges from 5 to 20 mg per day. The most common side effect is weight gain.",
"   </p>",
"   <p>",
"    The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    was established in five randomized trials that lasted 8 or 12 weeks; 639 patients with major depression received active drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/37,45,51,52\">",
"     37,45,51,52",
"    </a>",
"    ]. Olanzapine was generally started at 6 mg per day and increased every two weeks by increments of 6 mg per day as clinically indicated, to a maximum of 18 mg per day. The mean final dose was approximately 9 mg per day.",
"   </p>",
"   <p>",
"    In a pooled analysis of two randomized trials (N = 401), side effects that occurred in significantly more patients who received adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    than in those who received placebo included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight gain (35 versus 7 percent of patients)",
"     </li>",
"     <li>",
"      Increased appetite (32 versus 6 percent)",
"     </li>",
"     <li>",
"      Dry mouth (29 versus 9 percent)",
"     </li>",
"     <li>",
"      Somnolence (18 versus 5 percent)",
"     </li>",
"     <li>",
"      Peripheral edema (12 versus 1 percent)",
"     </li>",
"     <li>",
"      Hypersomnia (11 versus 2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with placebo, adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    caused a significantly greater increase in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight (4.9 versus 0.4 kg)",
"     </li>",
"     <li>",
"      Prolactin serum level (3.4 versus 0.9",
"      <span class=\"nowrap\">",
"       mcg/L)",
"      </span>",
"     </li>",
"     <li>",
"      Total cholesterol (15.1 versus 0.8",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432355\">",
"    <span class=\"h3\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    extended release for unipolar major depression is 300 or 150 mg per day. &nbsp;The 300 mg dose is slightly more efficacious, but discontinuation from treatment is nearly 75 percent higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"     28",
"    </a>",
"    ]. Use of the immediate release formulation is reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/53\">",
"     53",
"    </a>",
"    ]. The most common adverse effects with either formulation are dry mouth and sedation.",
"   </p>",
"   <p>",
"    The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    extended release was established in two randomized trials that lasted six weeks; 627 patients with major depression received a fixed dose of quetiapine extended release 150 or 300 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"     28",
"    </a>",
"    ]. A trial of adjunctive quetiapine immediate release found that a mean dose of 182 mg per day was efficacious (29 patients received quetiapine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a pooled analysis of two randomized trials (N = 936), side effects that occurred in more patients who received adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    extended release 300 or 150 mg per day than placebo included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dry mouth (40 and 27 versus 8 percent of patients; not tested statistically)",
"     </li>",
"     <li>",
"      Somnolence (26 and 23 versus 4 percent)",
"     </li>",
"     <li>",
"      Sedation (17 and 13 versus 4 percent)",
"     </li>",
"     <li>",
"      Dizziness (12 and 11 versus 6 percent)",
"     </li>",
"     <li>",
"      Fatigue (11 and 14 versus 4 percent)",
"     </li>",
"     <li>",
"      Constipation (11 and 6 versus 4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over six weeks, mean weight gain for adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    300 mg per day was 1.3 kg, quetiapine 150 mg per day was 0.9 kg, and placebo was 0.2 kg (not tested statistically) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatotoxicity due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], including a fatal case in an elderly patient who received 25 mg per day for nine days to treat agitation and insomnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21954784\">",
"    <span class=\"h3\">",
"     Risperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    for unipolar major depression ranges from 0.25 to 3 mg per day. The most common side effect is sedation and dry mouth, but both rates were low.",
"   </p>",
"   <p>",
"    The dose of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    was established in three randomized trials that lasted between four and eight weeks; 213 patients with major depression received active drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/30,57,58\">",
"     30,57,58",
"    </a>",
"    ]. Risperidone was started at 0.25 or 0.5 mg per day and generally increased by increments of 0.25 to 1 mg per day every several days as clinically indicated; the usual final dose was 1 to 1.5 mg per day.",
"   </p>",
"   <p>",
"    In the largest randomized trial of adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (N = 268), side effects that occurred in more patients who received risperidone than placebo included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somnolence (5 versus 2 percent of patients; not tested statistically)",
"     </li>",
"     <li>",
"      Dry mouth (5 percent versus 1 percent)",
"     </li>",
"     <li>",
"      Weight gain (4 percent versus 2 percent)",
"     </li>",
"     <li>",
"      Insomnia (4 percent versus 2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over six weeks, mean weight gain was higher with adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    than placebo (1.3 versus 0.1 kg; not tested statistically).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H494067\">",
"    <span class=\"h1\">",
"     COMBINATION TREATMENT FOR PSYCHOTIC DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar major depression with psychotic features (ie, delusions or hallucinations) is often treated with an antidepressant plus an antipsychotic, which is consistent with practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The acute and maintenance treatment of unipolar psychotic depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4105?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Maintenance treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433345\">",
"    <span class=\"h1\">",
"     MONOTHERAPY FOR NONPSYCHOTIC DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation antipsychotic monotherapy may be efficacious for nonpsychotic unipolar major depression, and thus an option when switching from an ineffective treatment regimen. However, these drugs can cause many side effects, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95248719\">",
"    <span class=\"h2\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    monotherapy can provide a small benefit for patients with major depression. A pooled analysis of four randomized trials (lasting six or eight weeks) compared quetiapine extended release (50, 150, or 300 mg per day) with placebo in 1752 patients with nonpsychotic unipolar major depression who were either untreated or did not respond satisfactorily to one antidepressant trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/4\">",
"     4",
"    </a>",
"    ]. Remission occurred in more patients who received quetiapine than placebo (37 versus 30 percent). Quetiapine thus provided one more remission than placebo for every 15 patients treated with each regimen.",
"   </p>",
"   <p>",
"    However, the four trials in the pooled analysis used either fixed or semi-fixed doses, which may underestimate differences that are achieved with a flexible dose schedule that more closely reflects clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/59\">",
"     59",
"    </a>",
"    ]. As an example, a subsequent randomized trial (not included in the pooled analysis) using flexible doses compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    extended release with placebo in older patients, and found a larger benefit than was seen in the pooled analysis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link&amp;anchor=H2540898#H2540898\">",
"     \"Diagnosis and management of late-life depression\", section on 'Quetiapine'",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Although these findings indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    extended release has some utility for major depression, ongoing concerns remain about safety issues and side effects, especially with long term treatment. Side effects observed in the randomized trials included dry mouth, sedation, dizziness, fatigue, increased appetite, weight gain, constipation, and blurred vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/19-21,60\">",
"     19-21,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95248726\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulpiride appears to be effective for major depression, and amisulpride may be as well:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A six-week randomized trial compared sulpiride (not available in the United States) with placebo as monotherapy in 171 patients with mild to moderate unipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/61\">",
"       61",
"      </a>",
"      ]. Reduction of depressive symptoms was significantly greater in patients who received sulpiride (mean dose 181 mg per day). The type and frequency of side effects were generally comparable, except that serum prolactin was abnormally high in 50 percent of the patients treated with sulpiride.",
"     </li>",
"     <li>",
"      An eight-week randomized trial found that amisulpride (50 mg per day) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      (20 mg per day) were comparable as monotherapy in 272 patients with unipolar major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31993/abstract/62\">",
"       62",
"      </a>",
"      ]. However, the lack of a placebo arm and low fixed dose of both treatments undermine the trial&rsquo;s validity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither sulpiride nor amisulpride are available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21956323\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In unipolar major depression, second-generation antipsychotics are indicated for patients with nonpsychotic depression that does not respond sufficiently to antidepressant monotherapy (the antipsychotic is generally added to the same antidepressant), as well as psychotic depression (the antipsychotic is started concurrently with an antidepressant). Second-generation antipsychotic monotherapy may be efficacious for nonpsychotic depressed patients. (See",
"      <a class=\"local\" href=\"#H493815\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21954769\">",
"       'Adjunctive treatment for nonpsychotic depression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H494067\">",
"       'Combination treatment for psychotic depression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H433345\">",
"       'Monotherapy for nonpsychotic depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      are similarly efficacious for short-term augmentation of an antidepressant that has not adequately treated an episode of major depression. Much of the benefit occurs within the first two weeks of treatment. Adjunctive second-generation antipsychotics may be effective for patients with either a minimal response to antidepressant monotherapy or a partial response. Clinicians can select a particular antipsychotic based upon its secondary clinical effects. (See",
"      <a class=\"local\" href=\"#H550095\">",
"       'Acute phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar major depression who have failed multiple treatment regimens and then responded to an adjunctive second-generation antipsychotic that is well tolerated, it is reasonable to continue the antipsychotic to prevent relapse. (See",
"      <a class=\"local\" href=\"#H550119\">",
"       'Maintenance phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Safety issues with adjunctive second-generation antipsychotics include the metabolic syndrome, neuroleptic malignant syndrome (NMS), and tardive dyskinesia. (See",
"      <a class=\"local\" href=\"#H432190\">",
"       'Safety issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of an adjunctive second-generation antipsychotic for nonpsychotic unipolar major depression is often lower than the dose used for schizophrenia or bipolar disorder. Short-term use of adjunctive atypical antipsychotics for depression is usually well tolerated; however, adverse effects such as akathisia, weight gain, and sedation lead patients to discontinue treatment at significantly greater rates than placebo. (See",
"      <a class=\"local\" href=\"#H540872\">",
"       'Dose, side effects, and drug-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/1\">",
"      Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/2\">",
"      Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/3\">",
"      Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009; 66:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/4\">",
"      Thase ME, Montgomery S, Papakostas GI, et al. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol 2013; 28:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/5\">",
"      Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/6\">",
"      Lakoski JM, Aghajanian GK. Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 1985; 24:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/7\">",
"      Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64 Suppl 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/8\">",
"      Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008; 597:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/9\">",
"      Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/10\">",
"      Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/11\">",
"      Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/12\">",
"      Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982; 4:173.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Treating Resistant Depression., Zohar J, Belmaker RH.  (Eds), PMA Publishing Corp, New York 1987. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/14\">",
"      Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients with",
"Major Depressive Disorder, Third Edition, 2010. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/17\">",
"      Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8:67.",
"     </a>",
"    </li>",
"    <li>",
"     Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Clinical Practice Guideline 90, National Institute for Health &amp; Clinical Excellence file://guidance.nice.org.uk/CG90 (Accessed on June 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/19\">",
"      Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/20\">",
"      Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009; 14:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/21\">",
"      Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/22\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/23\">",
"      Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/24\">",
"      Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/25\">",
"      Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/26\">",
"      Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010; :CD008121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/27\">",
"      Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety concerns. PLoS Med 2013; 10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/28\">",
"      Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010; 127:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/29\">",
"      Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/30\">",
"      Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/31\">",
"      Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/32\">",
"      Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010; 71:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/33\">",
"      Papakostas GI, Petersen TJ, Green C, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry 2005; 17:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/34\">",
"      Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/35\">",
"      Nelson JC, Thase ME, Bellocchio EE, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol 2012; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/36\">",
"      Nelson JC, Thase ME, Trivedi MH, et al. Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009; 11:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/37\">",
"      Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/38\">",
"      Carroll BJ. Antipsychotic drugs for depression? Am J Psychiatry 2010; 167:216; author reply 216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/39\">",
"      Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64:1349.",
"     </a>",
"    </li>",
"    <li>",
"     Berman RM, Hazel J, Swanink R, et al. Long term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder (Study CN138-164). Presented at the 161st Annual Meeting of the American Psychiatric Assoc, Washington DC, May 3-6, 2008",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/41\">",
"      McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009; 10:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/42\">",
"      Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/43\">",
"      Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/44\">",
"      Weisler RH, Khan A, Trivedi MH, et al. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. J Clin Psychiatry 2011; 72:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/45\">",
"      Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/46\">",
"      Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/47\">",
"      Citrome L. Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. J Clin Psychiatry 2011; 72:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/48\">",
"      Fava M, Wisniewski SR, Thase ME, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol 2009; 29:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/49\">",
"      Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/50\">",
"      Fava M, Mischoulon D, Iosifescu D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/51\">",
"      Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/52\">",
"      Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/53\">",
"      McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007; 24:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/54\">",
"      Shpaner A, Li W, Ankoma-Sey V, Botero RC. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008; 20:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/55\">",
"      El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004; 16:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/56\">",
"      Naharci MI, Karadurmus N, Demir O, et al. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry 2011; 168:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/57\">",
"      Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/58\">",
"      Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/59\">",
"      Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004; 161:2045.",
"     </a>",
"    </li>",
"    <li>",
"     Earley W, McIntyre A, Wang G, et al. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). Presented at the 8th International Forum on Mood and Anxiety Disorder, Vienna, Austria, 12-14 November, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/61\">",
"      R&uuml;ther E, Degner D, Munzel U, et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 1999; 32:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31993/abstract/62\">",
"      Cassano GB, Jori MC, AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14688 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31993=[""].join("\n");
var outline_f31_15_31993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21956323\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21954874\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493149\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493815\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21954769\">",
"      ADJUNCTIVE TREATMENT FOR NONPSYCHOTIC DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H430764\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550095\">",
"      - Acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H550103\">",
"      Minimal response compared with partial response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H539368\">",
"      Comparisons with other adjunctive treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550119\">",
"      - Maintenance phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432190\">",
"      Safety issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9371665\">",
"      - Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1244492\">",
"      - Tardive dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H540929\">",
"      - Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86138377\">",
"      - Suicidal thinking and behavior in young adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H540872\">",
"      Dose, side effects, and drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H432220\">",
"      - Aripiprazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H432348\">",
"      - Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H432355\">",
"      - Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21954784\">",
"      - Risperidone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H494067\">",
"      COMBINATION TREATMENT FOR PSYCHOTIC DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H433345\">",
"      MONOTHERAPY FOR NONPSYCHOTIC DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95248719\">",
"      Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95248726\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21956323\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4105?source=related_link\">",
"      Unipolar major depression with psychotic features: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=related_link\">",
"      Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31994="Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)";
var content_f31_15_31994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Muhamed Saric, MD, PhD, FACC, FASE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Itzhak Kronzon, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/15/31994/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/15/31994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic atherosclerotic plaques are a manifestation of systemic atherosclerosis. They are associated with general risk factors for atherosclerotic disease, including age, hypertension, and hypercholesterolemia, and are more common in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aortic atherosclerotic plaques are an important source of emboli, leading to cerebral (eg, transient ischemic attack, stroke), extremity or visceral embolization (",
"    <a class=\"graphic graphic_picture graphicRef54250 \" href=\"mobipreview.htm?2/61/3028\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Embolic events can occur spontaneously or can be induced by interventions including cardiac catheterization, arteriography, peripheral interventions, intraaortic balloon pumping, and cardiac or vascular surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general manifestations and treatment of cholesterol crystal embolism, diagnosis and medical and surgical management will be reviewed. Thromboembolism from unstable aortic plaques is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific considerations related to end-organ ischemia (kidney, gut, extremity) that may result from cholesterol crystal embolus are discussed in separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5888108\">",
"    <span class=\"h1\">",
"     ATHEROEMBOLISM VERSUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of emboli originate from atherosclerotic plaques: thromboemboli and atheroemboli (cholesterol crystal emboli). Although the underlying risk factors may be similar, the two can often be differentiated based upon associated conditions and clinical manifestations. This is an important distinction, since the prognosis and treatment differ. Thromboembolism from complex aortic plaques is common, particularly from thoracic aortic plaques. In comparison, cholesterol crystal embolism is fairly rare, but is probably under-recognized given its diverse presentations. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is some overlap, these two disorders can be distinguished from each other. Thromboembolism occurs when thrombus, which is usually superimposed on an atherosclerotic plaque, dislodges due to plaque rupture or other forces. The thromboemboli tend to be single and lodge in medium or large arteries. Thromboemboli from aortic atherosclerotic plaque most often result in transient ischemic attack or stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Acute ischemia of the extremities, intestines, or solid organs (eg, kidney, spleen) can also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term cholesterol crystal embolism is used synonymously with cholesterol embolism or atheroembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/10\">",
"     10",
"    </a>",
"    ]. Cholesterol crystal embolism occurs when atherosclerotic plaque is disrupted and cholesterol crystals within the plaque or portions of the plaque embolize distally. The debris showers into the circulation partially or totally occluding arterioles that are &lt;200 micrometers in diameter, leading to a myriad of occlusions that typically affect multiple organs. These characteristic sizes of atheroemboli were illustrated in an experimental study using human aortorenal endarterectomy specimens. Following ex vivo &ldquo;angioplasty&rdquo; of these specimens, thousands of fragments 20 to 40 micrometers in size, the approximate size of the human afferent arteriole, and hundreds &gt;100 micrometers in size, were collected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol embolization is most likely to occur in the male patient &gt;50 years of age, with risk factors for atherosclerosis following cardiac catheterization or a vascular procedure. Cholesterol crystal embolism is strongly associated with older age, with the average age being 66 years in a review of 221 published cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"     12",
"    </a>",
"    ]. Lighter-skinned individuals may be more often affected, but it is more likely that subtle skin manifestations are not recognized in patients with darker skin tones. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Skin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The incidence and prevalence of cholesterol crystal embolism are unknown. The published estimates are limited by suboptimal or unclear diagnostic criteria (such as solely relying on elevation of serum creatinine concentration after a procedure), and infrequent biopsy data. The full manifestations of the syndrome are probably rare. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cholesterol crystal embolization may arise spontaneously or as the result of instrumentation of the vasculature (eg, cardiac catheterization, arteriography, vascular surgery). The following observations are from some of the studies that have evaluated the incidence or prevalence of cholesterol crystal embolism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 519 patients with extensive thoracic aortic plaque on transesophageal echocardiography, cholesterol crystal embolism occurred in 1 percent of patients during a follow-up of more than three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 1011 patients who underwent infrarenal aortic and infrainguinal vascular surgery or angiographic manipulation, clinical and pathologic evidence of cholesterol crystal embolism was found in 2.9 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lower rates are seen after cardiac surgery (0.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/15\">",
"       15",
"      </a>",
"      ]. In a prospective observational study of 1786 patients undergoing cardiac catheterization, definite cholesterol crystal embolism was observed in 0.8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 493 patients who underwent aortoiliac stent placements, 72 bilateral, the incidence of atheroembolism was 1.6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many cases of cholesterol crystal embolism are not recognized clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/18\">",
"     18",
"    </a>",
"    ]. This issue was addressed in a prospective study of 60 patients with an acute myocardial infarction, one-half of whom were treated with thrombolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/19\">",
"     19",
"    </a>",
"    ]. All patients underwent coronary artery bypass graft surgery (CABG) within one month, and two muscle biopsy specimens and one skin biopsy specimen were obtained at the time of surgery. Seven patients (12 percent) had pathologic evidence of cholesterol crystal emboli in the muscle biopsy specimens, only one of whom had clinically evident disease.",
"   </p>",
"   <p>",
"    This finding of asymptomatic disease is consistent with the prevalence of cholesterol crystal embolism in autopsy studies in unselected patients that range from 0.7 to 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. Even higher rates of cholesterol embolization (up to 75 percent) are reported in retrospective autopsy studies in patients selected for atherosclerotic risk factors or following surgery or instrumentation, but these studies may overestimate the incidence of cholesterol crystal embolism due to selection bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to asymptomatic disease, it is probable that clinical manifestations of cholesterol crystal embolism are ascribed to other causes. This may be most likely with acute renal failure, where acute kidney injury is much more common than cholesterol crystal embolism, which will not be diagnosed unless tissue is available for pathology if there are no other manifestations of this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Renal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5888585\">",
"    <span class=\"h2\">",
"     Risk factors for aortic atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for developing cholesterol crystal embolism are largely those associated with developing general atherosclerotic disease such as smoking, hypercholesterolemia, hypertension, obesity, and diabetes. The data supporting these associations are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The \"classic\" risk factors of hypertension, age, and smoking have been correlated with severe atherosclerotic plaque in the thoracic aorta. This relationship was demonstrated with transesophageal echocardiography (TEE) in a population-based study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/23\">",
"     23",
"    </a>",
"    ]. Among those with aortic plaque, the odds of having complex plaque increased as systolic blood pressure increased (OR 1.43 for each 10 mmHg increase, 95% CI 1.10-1.87). Complex aortic plaque also correlated with hypertension treatment, controlling for age and history of smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cholesterol crystal embolization is directly related to the severity of atherosclerosis. Any factor that destabilizes atherosclerotic plaque can result in cholesterol crystal embolism. Embolization may be spontaneous or iatrogenic precipitated by vascular manipulation during arteriography or surgery. It was previously estimated that 50 to 60 percent of cases of cholesterol crystal embolization were spontaneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]. However, the increasing frequency of endovascular manipulations (eg, coronary, aortoiliac, renal) has increased the incidence of iatrogenic embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In one retrospective review, spontaneous embolism occurred in only 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal aortic aneurysms are a known source of cholesterol emboli. In a prospective study of 660 patients with abdominal aortic aneurysm that were followed for 1 to 60 months (mean 15 months), cholesterol crystal embolization was diagnosed in 2.9 percent of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link&amp;anchor=H181175588#H181175588\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Limb ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503780\">",
"    <span class=\"h3\">",
"     Plaque characteristics and location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cholesterol crystal embolism in patients with aortic atherosclerosis is markedly increased if transesophageal echocardiography reveals protruding plaques, particularly if &ge;4 mm in thickness; ulceration; or superimposed mobile thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/5,9,28-32\">",
"     5,9,28-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A correlation between complex plaque seen on two-dimensional transesophageal echocardiography (2D-TEE) and embolization phenomena was first noted in 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/30\">",
"     30",
"    </a>",
"    ]. Subsequent 2D-TEE studies found that complex plaques may give rise to either cholesterol crystal emboli or thromboemboli (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63285 \" href=\"mobipreview.htm?7/23/7540\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef57210 \" href=\"mobipreview.htm?35/57/36767\">",
"     movie 1",
"    </a>",
"    ). In a few case reports, cholesterol crystal embolism to the skin and kidneys was proven by biopsy in patients with complex plaques in the descending thoracic aorta on 2D-TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In another report, transesophageal echocardiography demonstrated mobile particulate matter in transit from a complex plaque in a patient who subsequently died after multisystem involvement from cholesterol crystal embolism (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64740 \" href=\"mobipreview.htm?32/21/33110\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plaque in the aortic arch is implicated as a risk factor for cerebral embolization. However, data are conflicting. In longitudinal population-based studies in non-selected individuals, complex aortic atherosclerosis does not appear to be associated with an increased risk of primary stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most reports evaluating secondary stroke risk have found that complex aortic atherosclerosis is a risk factor for recurrent stroke. This may be due to selection bias as the studies linking aortic atheroma and secondary stroke were usually performed in patients referred for TEE to evaluate a cardiac source of emboli rather than in a random population sample.",
"   </p>",
"   <p>",
"    Mechanistically, aortic plaque may be both a source of cerebral emboli and a marker of generalized atherosclerosis. Studies of aortic arch plaque have found a 12 to 14 percent risk of cerebral embolization, particularly when the plaque is ulcerated or mobile. On the other hand, aortic plaque may be a marker of aging and age is an independent predictor of cerebrovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atherosclerotic plaque in the thoracic aorta is typically associated with distal embolization (abdominal organs, lower extremities). However, retrograde flow from complex descending thoracic aortic plaques may be a source of cranial or upper extremity embolization. In a study of 94 patients using transesophageal echocardiography, retrograde diastolic flow reached the left subclavian artery in 60 percent, the left common carotid artery in 26 percent, and the brachiocephalic trunk in 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abdominal aorta and iliac arteries are commonly identified as a source for lower extremity cholesterol crystal embolization. In one surgical series of 62 patients, the aorta or iliac arteries were identified angiographically as the embolic source in 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atherosclerotic plaque in the femoral, popliteal, or subclavian arteries may also be a source of extremity embolization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503787\">",
"    <span class=\"h3\">",
"     Instrumentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic embolism is typically due to vascular manipulation during arteriography or surgery. Surgical procedures may disrupt atherosclerotic plaque as vessels are dissected, cross-clamped, or as an arteriotomy is made. Trauma is an unusual cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arteriography is a more common iatrogenic cause than surgery, accounting for as many as 85 percent of iatrogenic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/14\">",
"     14",
"    </a>",
"    ]. The source of the emboli in a review of 29 patients was the abdominal aorta (16 patients), iliac arteries (7 patients) and femoropopliteal arteries (6 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with atherosclerotic renal artery stenosis often have diffuse atherosclerosis and are at a relatively high risk for cholesterol crystal embolism after renal arteriography, with an overall incidence of about 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of arterial manipulation has been illustrated in several studies. In a prospective series of 1000 patients who underwent percutaneous coronary interventions, guiding catheter placement was associated with visible scraping of debris from the walls of the aorta in more than one-half of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/38\">",
"     38",
"    </a>",
"    ]. Clinical cholesterol crystal embolism was not seen, however, as ischemic events were not associated with visualization of debris in the catheter. Similarly, with renal artery angioplasty with stenting, grossly visible material (cholesterol crystals, atheromatous material and thrombus) are found in the embolic protection filter in 45 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=see_link\">",
"     \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503824\">",
"    <span class=\"h3\">",
"     Anticoagulation/thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol crystal embolism has been reported after the use of thrombolytic agents or anticoagulants (primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ). However, a causal relationship between the use of these medications and cholesterol crystal embolism has not been established and, based on available evidence, the overall risk appears to be low.",
"   </p>",
"   <p>",
"    In the 40 years since the introduction of thrombolytic therapy, a total of 30 cases as a complication of thrombolysis have been reported; 28 patients received a thrombolytic agent for acute myocardial infarction and 2 patients for deep venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. These case reports gave the impression that there might be a causal relationship between thrombolysis and cholesterol crystal embolism. However, there is no evidence to suggest that lysis of thrombus overlying atherosclerotic plaque leads to plaque destabilization and atheroembolism. There are no large-scale clinical trials that specifically addressed the issue of cholesterol crystal embolism in the setting of thrombolytic therapy. One small study of 60 patients found no differences in the rate of cholesterol crystal embolism between the patients who received thrombolysis and those who did not. The presence or absence of cholesterol crystal embolism in this study was based upon skin and muscle biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/19\">",
"     19",
"    </a>",
"    ]. However, given the low incidence of embolism and the small number of patients in the study, a significant difference may not have been detectable.",
"   </p>",
"   <p>",
"    Cholesterol crystal embolism has also been blamed on therapy with anticoagulant drugs, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , with plaque hemorrhage as the putative precipitating factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, it is unclear if cholesterol crystal embolism was caused by anticoagulants or it simply occurred in patients who happened to be on anticoagulation therapy. Trials that have randomly assigned patients with documented aortic plaque identified by transesophageal echocardiography to anticoagulant therapy have not identified an increased risk for atheroembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/13,16,45,46\">",
"     13,16,45,46",
"    </a>",
"    ]. Thus, the putative risk associated with anticoagulation therapy appears to be low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variability in clinical manifestation is related to the location of the embolic source, extent of embolization, whether there is partial or complete occlusion of the affected vessels, and the presence or absence of preexisting disease in the affected vascular bed (eg, peripheral artery disease).",
"   </p>",
"   <p>",
"    Atheroemboli from the aortic arch typically embolize to the brain, eye, or upper extremity while descending thoracic or abdominal aortic plaque causes gastrointestinal or lower extremity symptoms and signs. Retrograde embolization from the thoracic aorta can also occur. (See",
"    <a class=\"local\" href=\"#H1503780\">",
"     'Plaque characteristics and location'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presenting symptoms of cholesterol crystal embolism may be subtle and nonspecific. As an example, 21 percent of patients in a review of 221 cases presented with systemic symptoms of fever, myalgias, headache, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"     12",
"    </a>",
"    ]. Often there is a delay between the embolic event and subsequent symptoms. In a review of histologically proven cholesterol embolization, skin signs developed more than 30 days after a precipitating event in 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More dramatic clinical presentations are generally due to a diffuse showering of larger, atheromatous debris originating from usually aortic plaque. The emboli may lodge into the renal, mesenteric, pelvic, carotid, coronary, or extremity vascular beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/48\">",
"     48",
"    </a>",
"    ]. Classic manifestations include \"blue toe syndrome,\" livedo reticularis, acute or subacute renal failure, and intestinal ischemia. Other manifestations include gastrointestinal bleeding and pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin findings are the most common clinical sign of cholesterol crystal embolism, occurring in 34 percent of patients in one systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"     12",
"    </a>",
"    ]. In this study, the most frequent findings included livedo reticularis (16 percent), gangrene (12 percent), cyanosis (10 percent), skin ulcer (6 percent), purpura or petechiae (5 percent) and firm, painful erythematous nodules (3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"     12",
"    </a>",
"    ]. Splinter hemorrhages have also been described as a possible cutaneous manifestation of cholesterol crystal embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/49\">",
"     49",
"    </a>",
"    ]. Gangrene and ulcerations typically affect the toes but may extend to more proximal portions of the lower extremities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These classic skin findings in cholesterol crystal embolism commonly occur in areas where the arterial pulse is palpable, since the embolization is to smaller arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12,47,50\">",
"     12,47,50",
"    </a>",
"    ]. However, the arterial pulse may not be palpable in patients who also have underlying peripheral artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cholesterol crystal embolization to the skin of the genitalia is rare, but when it occurs, can lead to severe scrotal or penile skin loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. This devastating complication has been reported following open and, more recently, endovascular repair of abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505321\">",
"    <span class=\"h3\">",
"     Livedo reticularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Livedo reticularis is a reticulated, mottled or erythematous skin discoloration which blanches on pressure (",
"    <a class=\"graphic graphic_picture graphicRef71860 \" href=\"mobipreview.htm?39/58/40866\">",
"     picture 2",
"    </a>",
"    ). It may be red or blue, and even ulcerated, depending on the degree of blood flow compromise and oxygen desaturation through the affected area. Livedo reticularis is not specific for atheroembolism and has an extensive differential diagnosis. In patients with cholesterol crystal embolization, livedo reticularis is usually bilateral and is typically found on the feet and lower legs but may extend toward the thighs, buttocks, and the back. Upper extremities are less commonly involved.",
"   </p>",
"   <p>",
"    In patients undergoing abdominal aortic aneurysm repair, livedo reticularis may appear on the back and the buttocks due to cholesterol embolization into the branches of the internal iliac arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120148342\">",
"    <span class=\"h3\">",
"     Blue toe syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cholesterol crystal embolization is often referred to as the &ldquo;blue toe syndrome&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef58761 \" href=\"mobipreview.htm?2/15/2289\">",
"     picture 3",
"    </a>",
"    ), blue skin discoloration is less common than other skin findings. In the overall population of patients with cholesterol embolization syndrome, skin manifestations are seen in only about a third of such patients, and of these, blue toes are present in 10 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12,18,47\">",
"     12,18,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 78 patients with cutaneous manifestations of cholesterol crystal embolization, blue toes were noted in 14 percent of the patients. More common skin manifestations were livedo reticularis (49 percent), gangrene (35 percent), cyanosis (28 percent) and ulceration (17 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 221 patients, skin manifestations were present in 75 patients. Of these 75, blue toes were observed in 11 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury is a common manifestation of cholesterol crystal embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/26,54\">",
"     26,54",
"    </a>",
"    ]. The characteristics of renal involvement are discussed in detail separately (",
"    <a class=\"graphic graphic_picture graphicRef56672 graphicRef68445 \" href=\"mobipreview.htm?26/2/26665\">",
"     picture 4A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=see_link\">",
"     \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury is present in 25 to 50 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12,15,24\">",
"       12,15,24",
"      </a>",
"      ]. Renal disease most often occurs after invasive vascular procedures, but can occur spontaneously. In such patients, the diagnosis may be difficult to establish without biopsy unless other manifestations of crystal embolism are present.",
"     </li>",
"     <li>",
"      Because the cholesterol crystal emboli are irregularly shaped and nondistensible, and typically do not completely occlude larger vessels, the renal manifestations are those of distal parenchymal ischemia usually manifested as a bland sediment rather than renal infarction as seen with thromboemboli, which present with flank pain, hematuria that may be gross, and markedly elevated serum lactate dehydrogenase.",
"     </li>",
"     <li>",
"      When acute kidney injury occurs after arteriography, the primary differential diagnosis is contrast nephropathy and cholesterol crystal embolism. Unless there are other signs of cholesterol crystal embolism, the two disorders are distinguished by differences in the clinical course. Contrast nephropathy typically begins to recover within three to five days, while cholesterol crystal embolism shows at best an incomplete recovery and there may be a stuttering course with further showers of cholesterol crystals. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although not a common manifestation of cholesterol crystal embolism, rhabdomyolysis has been reported in association with massive cholesterol crystal embolism and can lead to heme-pigment-associated acute kidney injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/55\">",
"       55",
"      </a>",
"      ]. Rhabdomyolysis presents with elevated serum muscle enzymes (including creatine kinase), red to brown urine due to myoglobinuria if there is persistent renal function, and electrolyte abnormalities. Peak serum creatine kinase levels depend upon the volume of muscle breakdown and the muscle mass of the patient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=see_link\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atheroembolism to the mesenteric circulation most commonly involves the colon, small bowel, and stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/56\">",
"     56",
"    </a>",
"    ]. The pancreas, liver, and gallbladder also may be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=see_link\">",
"     \"Colonic ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrointestinal manifestations include abdominal pain, diarrhea, and, in about 10 percent of patients, bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12,56,58\">",
"     12,56,58",
"    </a>",
"    ]. Bleeding may originate from any site in the gastrointestinal tract, including the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/59\">",
"     59",
"    </a>",
"    ]. Other manifestations of cholesterol crystal embolism include necrotizing pancreatitis, focal hepatic cell necrosis, and acalculous necrotizing cholecystitis. Intestinal infarction has a poor prognosis, with reported mortality rates ranging from 38 to 81 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12,60\">",
"     12,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upper endoscopic findings of nonspecific entities such as gastritis may be erroneously diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/59\">",
"     59",
"    </a>",
"    ]. A definitive diagnosis can only be established by examination of a biopsy specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H395442939\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system manifestations of atheroembolism may include amaurosis fugax, transient ischemic attack, stroke, confusional state, headache, dizziness, or organic brain syndrome. Embolization to the spinal cord is rare but can lead to lower extremity paralysis",
"   </p>",
"   <p>",
"    Transient ischemic attack due to atheroembolic debris is more commonly associated with carotid atherosclerotic disease, and carotid thrombosis or thromboembolism can lead to hemispheric stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and classification of stroke\", section on 'Embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting data regarding the stroke risk associated with aortic atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/4,5,34,61-65\">",
"     4,5,34,61-65",
"    </a>",
"    ]. Large protruding plaques in the aortic arch, particularly mobile plaques, in our opinion, are an important cause of brain pathology. In one retrospective review of 29 patients with cholesterol emboli in the brain identified on autopsy, encephalopathy presumably due to ischemia was the predominant clinical finding and was most likely due to bilateral diffuse embolization from the identified aortic plaque disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical longitudinal population studies in unselected patients, complex aortic atherosclerosis does not appear to be associated with an increased risk for primary ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/34,62,63\">",
"     34,62,63",
"    </a>",
"    ]. However, most studies have found that complex aortic atherosclerosis is a risk factor for recurrent stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/4,5,64,65\">",
"     4,5,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of findings is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study examined the frequency and thickness of atherosclerotic plaques in the ascending aorta and proximal arch in 250 patients admitted to the hospital with ischemic stroke and 250 consecutive controls, all over the age of 60 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/5\">",
"       5",
"      </a>",
"      ]. Atherosclerotic plaques &ge;4 mm in thickness were found in 14 percent of patients compared with 2 percent of controls, and the odds ratio for ischemic stroke among patients with such plaques was 9.1 after adjustment for atherosclerotic risk factors. In addition, aortic atherosclerotic plaques &ge;4 mm were much more common in patients with brain infarcts of unknown cause (relative risk 4.7).",
"     </li>",
"     <li>",
"      In contrast, a population-based study of 1135 subjects who had transesophageal echocardiography (TEE) found that complex atherosclerotic plaque (&gt;4 mm with or without mobile debris) in the ascending and transverse aortic arch was not a significant risk factor for cryptogenic ischemic stroke or TIA after adjusting for age, gender, and other clinical risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/62\">",
"       62",
"      </a>",
"      ]. However, there was an association between complex aortic plaque and non-cryptogenic stroke. The investigators concluded that complex aortic arch debris is a marker for the presence of generalized atherosclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methodologic differences are a potential explanation for the discrepant results of these reports assessing the risk of ischemic stroke related to aortic atherosclerosis, as the earlier case-control studies may have been skewed by selection and referral bias. However, many patients with aortic atherosclerosis also have cardiac or large artery lesions, a problem that may confound purely epidemiologic studies",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184668148\">",
"    <span class=\"h3\">",
"     Ocular signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hollenhorst plaques are bright, refractile lesions in the retina indicative of cholesterol crystal embolization from a proximal atherosclerotic source (",
"    <a class=\"graphic graphic_picture graphicRef63740 \" href=\"mobipreview.htm?23/3/23601\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/67\">",
"     67",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The most common proximal source is the carotid artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In a review of 130 patents with Hollenhorst plaque or retinal artery occlusion (amaurosis excluded), 61 percent complained of ocular symptoms including eye pain, blurred vision or other atypical visual symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/70\">",
"     70",
"    </a>",
"    ]. Of the 98 patients who underwent carotid duplex, all had some evidence of carotid stenosis ipsilateral to the ocular findings but the degree of stenosis was less than 60 percent in 90 of the 130 patients. Over a mean of 22 months, no patient suffered from a transient ischemic attack (including amaurosis fugax) or stroke. Evaluation of the more central vasculature was performed in about 20 percent of the patients and, although some minor valvular problems were found, a cardiac or aortic source for the retinal findings was not found.",
"   </p>",
"   <p>",
"    Cholesterol embolization resulting in Hollenhorst plaques can occur following arteriography or cardiac catheterization, vascular surgery, or trauma. The mere finding of Hollenhorst plaques in a patient presenting with suspected cholesterol embolization syndrome should not be used to confirm that the acute clinical presentation is due to cholesterol emboli. A finding of Hollenhorst plaque may represent a prior event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In one study, serial funduscopic examination found persistence of Hollenhorst plaques for over a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/69\">",
"     69",
"    </a>",
"    ]. Moreover, about one-third of patients who have Hollenhorst plaques are asymptomatic. Thus, additional evaluation may be needed to confirm the diagnosis of acute cholesterol embolization syndrome. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505795\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other vascular beds including coronary, pulmonary, prostate, thyroid and adrenal glands may rarely be affected with diagnosis usually established at autopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of cholesterol crystal embolization should be highly suspected in a patient with known atherosclerotic disease and a classic history: the development of renal failure, abdominal pain or diarrhea, typical skin findings or a finding of Hollenhorst plaques of the retina following arteriography, cardiac catheterization, vascular surgery, or trauma to the abdomen. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laboratory testing is generally nonspecific and may show elevations in the white blood cell count, decreased red blood cell count, or thrombocytopenia. Inflammation markers including elevated erythrocyte sedimentation rate, C-reactive protein and fibrinogen have been associated with atheroembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/16\">",
"     16",
"    </a>",
"    ]. Other abnormalities may include transient hypocomplementemia and eosinophilia.",
"   </p>",
"   <p>",
"    Because there is an association between occlusive diseases in large peripheral arteries and cholesterol crystal embolization to smaller arteries, patients with extremity embolism should undergo noninvasive vascular testing to identify the presence of hemodynamically significant proximal peripheral artery disease. Even when a stenotic peripheral artery may not be the source of cholesterol crystal embolism, arterial revascularization may improve clinical outcomes. (See",
"    <a class=\"local\" href=\"#H1506544\">",
"     'Revascularization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific abnormalities may indicate end-organ dysfunction such as increased creatinine or eosinophiluria if the kidneys are involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/73-76\">",
"     73-76",
"    </a>",
"    ], increased amylase with pancreatic (and possibly bowel) involvement, elevated transaminases with hepatic involvement or elevated creatine kinase and myoglobinuria with sufficient muscle involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5888663\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaques in the aorta can be visualized, characterized and quantified by a variety of imaging techniques; however, the index plaque that is the cause of the cholesterol crystal embolization is rarely determined. The diagnosis is more difficult in patients without typical clinical features, particularly if cholesterol crystal embolism has occurred spontaneously. However, the identification of complex aortic plaque or multiple ischemic strokes on imaging studies may permit a presumptive diagnosis to be made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/5,28,29\">",
"     5,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plaques can be simple or complex (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72777 \" href=\"mobipreview.htm?20/39/21104\">",
"     image 3",
"    </a>",
"    ). Simple plaques are characterized by wall thickness &lt;4 mm and the absence of mobile components. Complex plaques are &ge;4 mm in thickness, and may exhibit irregular borders, ulceration and mobile components which represent superimposed thrombus. Complex plaques are associated with an increased propensity for embolization. (See",
"    <a class=\"local\" href=\"#H1503780\">",
"     'Plaque characteristics and location'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Transesophageal echocardiography, primarily two-dimensional (2D) transesophageal echocardiography (TEE), is the first-line diagnostic modality to identify a thoracic aortic source of atheroembolism. Real-time three-dimensional transesophageal echocardiography (3D-TEE) provides very detailed information on aortic plaque location and morphology (",
"    <a class=\"graphic graphic_picture graphicRef56112 \" href=\"mobipreview.htm?15/12/15554\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70016 \" href=\"mobipreview.htm?23/31/24063\">",
"     movie 2",
"    </a>",
"    ). Transthoracic echocardiography, abdominal ultrasound, and endoscopic ultrasound (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63026 \" href=\"mobipreview.htm?1/2/1059\">",
"     image 4",
"    </a>",
"    ) of the upper gastrointestinal tract have occasionally incidentally identified atherosclerotic plaques in the thoracic or abdominal aorta.",
"   </p>",
"   <p>",
"    Compared with TEE, computed tomography (CT) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75835 \" href=\"mobipreview.htm?4/1/4118\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68662 \" href=\"mobipreview.htm?29/60/30659\">",
"     movie 3",
"    </a>",
"    ) and magnetic resonance imaging (MRI) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55892 \" href=\"mobipreview.htm?26/4/26690\">",
"     image 6",
"    </a>",
"    ) are less invasive and more complete evaluations of the extent of atherosclerosis in the aorta. CT and MRI have several advantages over TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. These radiologic techniques are better than TEE for imaging aortic branches. In addition, they can image the entire abdominal aorta. In comparison, only the very proximal abdominal aorta between the diaphragm and the ostium of the superior mesenteric artery can be seen with TEE.",
"   </p>",
"   <p>",
"    Conventional arteriography has low sensitivity for detection of plaques and often fails to identify plaques detected by other imaging techniques and should be avoided given the potential disruption of atherosclerotic debris with instrumentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1503787\">",
"     'Instrumentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Radiologic studies of the brain may help suggest the diagnosis in demonstrating multiple small ischemic lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5889574\">",
"    <span class=\"h2\">",
"     Biopsy and pathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is the only definitive means of confirming the diagnosis of cholesterol embolization syndrome. Thus, biopsy should be performed whenever the diagnosis is in doubt and when the specimen can safely be obtained from the patient. Histopathologic examination of amputated body parts or embolectomy specimens for cholesterol emboli pose no additional risk to the patient and should be performed if the diagnosis is suspected. Skin and skeletal biopsies are less invasive than renal and gastrointestinal biopsies.",
"   </p>",
"   <p>",
"    The histologic hallmark of cholesterol crystal embolism is the presence of \"ghosts\" of cholesterol crystals or cholesterol clefts within arterioles, since the cholesterol crystals are dissolved during tissue fixation (",
"    <a class=\"graphic graphic_picture graphicRef56672 graphicRef68445 \" href=\"mobipreview.htm?26/2/26665\">",
"     picture 4A-B",
"    </a>",
"    ). The cholesterol clefts are crescentic (with pointed ends) or elongated ovoid spaces present in small or medium-sized arteries or arterioles. Inflammatory or fibrous intimal proliferation develops rapidly, and may be the cause for vascular occlusion and resultant ischemic tissue damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholesterol clefts have also been demonstrated in the pulmonary arteries of patients with cholesterol crystal embolism. Since pulmonary arterial atherosclerosis is rare (eg, in end-stage Eisenmenger syndrome), the crystals presumably pass through the systemic capillary bed into the venous system and lungs. In a case report, cholesterol crystal emboli were seen in 25 percent of the small pulmonary arteries in a patient with atheroembolic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5889718\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is often difficult to establish when the presenting symptoms and signs of cholesterol crystal embolism are subtle and nonspecific. Cholesterol crystal embolism needs to be distinguished from thromboembolism given differences in treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link&amp;anchor=H10#H10\">",
"     \"Embolism from aortic plaque: Thromboembolism\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of its many differing effects, cholesterol crystal embolism may be included as one of the \"great imitators,\" (such as tuberculosis, brucellosis) given its often nonspecific symptoms, leading it to be confused with a number of other diseases, including vascular diseases such aortic dissection, and tumors such as left atrial myxoma, lymphoma, and renal cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/48\">",
"     48",
"    </a>",
"    ]. The differential diagnosis includes many systemic illnesses including cyanotic congenital heart disease, secondary syphilis, and pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also an extensive differential diagnosis of livedo reticularis that includes Raynaud's phenomenon, vasculitis (polyarteritis nodosa, systemic lupus, dermatomyositis, leukocytoclastic angiitis, rheumatoid vasculitis, thromboangiitis obliterans), infection (syphilis or tuberculosis), cryoglobulinemia, antiphospholipid syndrome, and polycythemia vera. A familial form called Sneddon's syndrome is seen in association with cerebrovascular disease.",
"   </p>",
"   <p>",
"    Among patients who develop acute kidney injury, particularly if the sediment is relatively bland, the differential renal diagnosis includes contrast nephropathy and acute kidney injury, both of which are typically reversible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=see_link\">",
"     \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for cholesterol embolization comprises managing cardiovascular risk factors, management of end-organ ischemia, and prevention of recurrent embolization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120149438\">",
"    <span class=\"h2\">",
"     Risk factor management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cholesterol crystal embolism should be aggressively treated for secondary prevention of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/82\">",
"     82",
"    </a>",
"    ]. These modalities include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , statins, blood pressure control, cessation of smoking, and, in patients with diabetes, glycemic control. (See",
"    <a class=\"local\" href=\"#H1506317\">",
"     'Statin therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503064\">",
"    <span class=\"h2\">",
"     Managing ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the microvascular obstruction leading to end-organ ischemia varies depending upon the vascular bed affected, but is primarily supportive. The general principles of managing transient ischemic attack, stroke, renal embolization or infarction, gastrointestinal ischemia or infarction, and extremity ischemia are discussed in separate topic reviews.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11367?source=see_link\">",
"     \"Diagnosis and treatment of renal infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inflammatory reaction that results from cholesterol crystal embolization is essentially a foreign body reaction to the cholesterol crystals which are resistant to breakdown by macrophages. Arterioles that are not immediately occluded may occlude as a chronic inflammatory infiltrate fills the lumen. Given this pathologic mechanism, various antiinflammatory and antithrombotic agents have been used in an attempt to lessen the inflammatory reaction to prevent thrombosis.",
"   </p>",
"   <p>",
"    There are no large trials evaluating antiinflammatory therapies for treating cholesterol crystal embolism. Isolated reports in small numbers of patients using steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/83-88\">",
"     83-88",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/89,90\">",
"     89,90",
"    </a>",
"    ], and LDL apheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/91-93\">",
"     91-93",
"    </a>",
"    ], have shown modest success.",
"   </p>",
"   <p>",
"    The inflammatory nature of cholesterol crystal embolism results in pain that is often out of proportion to the apparent degree of tissue ischemia and pain management is of critical importance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    Aggressive saline hydration is the primary initial therapy of myoglobinuria, lowering the risk of induction of acute kidney injury. Other treatments may include bicarbonate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . The prevention and treatment of heme pigment-induced acute kidney injury is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503460\">",
"    <span class=\"h2\">",
"     Preventing recurrent embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment to prevent recurrent cholesterol crystal embolization is not clear. Secondary prevention seems warranted, particularly since aortic plaques &ge;4 mm in size appear to be associated with an increased risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/6,94,95\">",
"     6,94,95",
"    </a>",
"    ]. In patients whose cholesterol embolization syndrome was precipitated by instrumentation (such as arteriography, cardiac catheterization or vascular surgery), any further invasive imaging or treatment should be avoided unless absolutely necessary. Noninvasive ultrasound, CT or MRI imaging should replace the invasive techniques whenever possible. When arterial cannulation is absolutely necessary, alternative access routes should be considered (eg, cardiac catheterization via radial artery approach in a patient with extensive plaques in the descending thoracic aorta).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1506317\">",
"    <span class=\"h3\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy may decrease the risk of future embolization. Statins lower LDL-cholesterol and have a variety of other effects, one of which appears to be plaque stabilization. In a retrospective study of 519 patients with severe thoracic aortic plaque cited, statin therapy was associated with a significantly lower rate of recurrent stroke and thromboembolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the number of patients with atheroembolization was too small (five) for subset analysis. On multivariate analysis, the protective effect seen with statin therapy was not present for patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or antiplatelet agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link&amp;anchor=H4#H4\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\", section on 'Plaque stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503486\">",
"    <span class=\"h3\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy for the treatment of cholesterol crystal embolism remains controversial. Although it seems intuitive that anticoagulation would improve arterial patency, the obstruction is mostly due to the atheroembolic debris and the inflammatory reaction it incites, and not thrombus. Another important consideration is the association between anticoagulant and antithrombotic therapy and the development of cholesterol crystal embolism; however, due to paucity of data, a causal relationship between cholesterol crystal embolism and anticoagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombolytic therapy can be neither proven nor refuted with certainty. (See",
"    <a class=\"local\" href=\"#H1503824\">",
"     'Anticoagulation/thrombolytic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no randomized trials that have evaluated the role of antithrombotic therapy in patients with aortic atheroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/94,96\">",
"     94,96",
"    </a>",
"    ]. Nonrandomized retrospective studies have shown a benefit of oral anticoagulation over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with mobile thrombi in the aortic arch. Based on this low quality evidence, the 2012 ACCP guidelines panel suggested oral anticoagulation or antiplatelet agents for patients with cryptogenic stroke and mobile aortic arch thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40105?source=see_link&amp;anchor=H23#H23\">",
"     \"Cryptogenic stroke\", section on 'Prevention and treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the 2012 ACCP guidelines stated that the hemorrhagic complications may outweigh the benefits of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/96\">",
"     96",
"    </a>",
"    ]. Other studies have not shown a benefit to anticoagulation. In a retrospective review of 519 patients with complex plaque, cholesterol crystal embolism occurred in only five (1 percent) during a follow-up of more than three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk was similar in the patients treated (2 of 206) and not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (3 of 313). This rate is similar to that noted in the Stroke Prevention in Atrial Fibrillation (SPAF-III) trial (1 of 134 warfarin-treated patients), most of whom had severe atherosclerotic plaques on transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we do not routinely use anticoagulants in patients who are diagnosed with cholesterol crystal embolism unless they have other indications for anticoagulation (such as atrial fibrillation or mechanical prosthetic valve). Definitive recommendations regarding the use of anticoagulant in this context should await the results of an ongoing randomized trial comparing oral anticoagulant with antiplatelet therapy in patients with thoracic aortic plaque. The ARCH trial is an ongoing international randomized controlled study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) for the prevention of stroke in patients with aortic arch atheroma that is either mobile or &ge;4 mm thick [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to emphasize that the package insert for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    explicitly states that warfarin therapy may increase the risk of cholesterol crystal embolism and that discontinuation of warfarin is recommended when cholesterol crystal embolism is observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Plaque removal or exclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the poor outcomes associated with cholesterol crystal embolism, surgical plaque removal (endarterectomy) or exclusion of the plaque (ligation and bypass, endovascular exclusion) may be indicated if a clear embolic source is identified, the source is surgically accessible, and the patient is an appropriate candidate for surgery. Patients with lower extremity symptoms and an infrarenal source for embolism may have more favorable outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 100 patients who underwent surgery over a 12-year period following identification of the embolic source, occlusive aortoiliac disease (47 patients) and small aortic aneurysms (20 patients) were the most commonly identified embolic sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common surgical treatment was aortic bypass. Other procedures included aortoiliac endarterectomy with patching, femoral or popliteal endarterectomy, and infrainguinal or upper extremity bypass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12245?source=see_link\">",
"     \"Overview of upper extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this study the reported outcomes were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative mortality &ndash; 11 percent (all had a suprarenal aortic thrombus preoperatively)",
"     </li>",
"     <li>",
"      Survival rates at one, three and five years &ndash; 89, 83, and 73 percent, respectively",
"     </li>",
"     <li>",
"      Toe and leg amputations &ndash; 9 and 10 percent, respectively",
"     </li>",
"     <li>",
"      Hemodialysis &ndash; 10 percent",
"     </li>",
"     <li>",
"      Recurrent emboli &ndash; 5 percent within eight months of surgery with no further emboli over the next three years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another surgical series of 62 patients who underwent surgery at one institution, bypass grafts were inserted in 42 patients after exclusion of the native diseased artery, 20 had endarterectomies (6 of them with bypass grafts), and 5 were treated medically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/24\">",
"     24",
"    </a>",
"    ]. The 30-day mortality rate was 5 percent. \"Minor\" amputation was required in 19 patients (31 percent), and leg amputation in 2 patients. Limb salvage was possible in 86 of 88 limbs. There were no postoperative embolic incidents in the involved limbs during a mean follow-up of 20 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17713880\">",
"    <span class=\"h3\">",
"     Covered stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;More recently, covered stents and endografts have been used to exclude the involved arterial segment in a small number of patients with aortic or iliac artery sources of cholesterol crystal embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/27,101\">",
"     27,101",
"    </a>",
"    ]. The disadvantage of this technique compared with open surgery is a greater risk for recurrent embolization related to the intraluminal manipulation of guidewires [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/17\">",
"     17",
"    </a>",
"    ]. Definitive recommendations for the use of covered stents are not possible at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1506544\">",
"    <span class=\"h3\">",
"     Revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with lower extremity cholesterol embolism and a hemodynamically significant proximal stenosis (that may or may not be the source of embolism), arterial revascularization can restore normal pressures, improve distal perfusion and may improve pain. (See",
"    <a class=\"local\" href=\"#H1503064\">",
"     'Managing ischemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgical (eg, bypass) or endovascular (eg, stent) management may be appropriate depending on the location of the obstruction. Percutaneous angioplasty and stenting, mostly of the iliac and femoral arteries, have been performed in a small number of patients without causing recurrent embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/100,102\">",
"     100,102",
"    </a>",
"    ]. The decision on whether to perform revascularization in patients with cholesterol embolization syndrome should also take into account the severity and duration of ischemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5890461\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in medically treated patients with cholesterol crystal emboli is poor, in part because of severe underlying atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/103\">",
"     103",
"    </a>",
"    ]. Acute, in-hospital mortality was 16 percent (4 of 25) in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/16\">",
"     16",
"    </a>",
"    ], but mortality rates may be as high as 80 percent when cases that are diagnosed post-mortem are included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5886720\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atheroembolism, also known as cholesterol crystal embolism or cholesterol embolism refers to arterio-arterial embolism of cholesterol crystals or small pieces of atheromatous material originating from an atherosclerotic plaque usually from the aorta but occasionally from other arteries. Cholesterol crystal embolism results in partial or total occlusion of small arteries, leading to tissue or organ ischemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for atheroembolism include patient factors such as hypertension, advancing age, smoking, hypercholesterolemia, obesity, and diabetes. Anatomic factors associated with the aortic atherosclerotic plaque such as plaque thickness &ge;4 mm, plaque ulceration, or the presence of mobile debris increases the risk for embolization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of cholesterol crystal embolism should be suspected in patients with known atherosclerotic disease and the development of renal failure, transient ischemic attack, cerebral infarction, signs of intestinal ischemia, digital ischemia, typical skin findings or Hollenhorst plaques in the retina particularly following arteriography, cardiac catheterization, vascular surgery, or trauma to the abdomen. The diagnosis is more difficult in patients who do not have these features, particularly if cholesterol crystal embolism has occurred spontaneously. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of complex aortic plaque on imaging studies supports the diagnosis. Atherosclerotic plaques can also be seen using transthoracic echocardiography, abdominal ultrasound and endoscopic ultrasound of the upper gastrointestinal tract. (See",
"      <a class=\"local\" href=\"#H5888663\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing is generally nonspecific but may indicate the effects of end-organ ischemia. A definitive diagnosis depends upon pathologic specimens. Biopsy should be performed whenever the diagnosis is in doubt and when the specimen can safely be obtained from the patient; debrided or amputated tissue and thrombectomy specimens should be sent for pathologic examination since these represent no risk to the patient. The histologic hallmark of cholesterol crystal embolism is the presence of \"ghosts\" of cholesterol crystals or cholesterol clefts within arterioles. (See",
"      <a class=\"local\" href=\"#H5889574\">",
"       'Biopsy and pathologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of cholesterol crystal embolism is primarily medical, consisting of risk-factor reduction. Statin therapy is indicated as part of risk-factor reduction and appears to reduce the rate of recurrent embolism. (See",
"      <a class=\"local\" href=\"#H1506317\">",
"       'Statin therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical or endovascular treatment may be indicated if a clear embolic source is identified, the source is anatomically suitable, and the patient is an appropriate candidate for surgery. For patients who meet these criteria, we suggest surgical or endovascular treatment to remove or exclude the embolic source (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      routinely anticoagulating patients who are diagnosed with cholesterol crystal embolism (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , and use of thrombolytic therapy are all associated with the development of cholesterol embolism, although a causal relationship has never been demonstrated. However, patients with another indication for anticoagulation, such as thromboembolism or deep vein thrombosis, should be treated. (See",
"      <a class=\"local\" href=\"#H1503064\">",
"       'Managing ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis in patients with cholesterol crystal embolism correlates with the degree of the underlying atherosclerosis, and is overall poor. (See",
"      <a class=\"local\" href=\"#H5890461\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/1\">",
"      Fazio GP, Redberg RF, Winslow T, Schiller NB. Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease. J Am Coll Cardiol 1993; 21:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/2\">",
"      Matsuzaki M, Ono S, Tomochika Y, et al. Advances in transesophageal echocardiography for the evaluation of atherosclerotic lesions in thoracic aorta--the effects of hypertension, hypercholesterolemia, and aging on atherosclerotic lesions. Jpn Circ J 1992; 56:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/3\">",
"      Tunick PA, Kronzon I. Atheromas of the thoracic aorta: clinical and therapeutic update. J Am Coll Cardiol 2000; 35:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/4\">",
"      Amarenco P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992; 326:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/5\">",
"      Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/6\">",
"      Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med 1996; 334:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/7\">",
"      Karalis DG, Quinn V, Victor MF, et al. Risk of catheter-related emboli in patients with atherosclerotic debris in the thoracic aorta. Am Heart J 1996; 131:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/8\">",
"      Katz ES, Tunick PA, Rusinek H, et al. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: experience with intraoperative transesophageal echocardiography. J Am Coll Cardiol 1992; 20:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/9\">",
"      Tunick PA, Rosenzweig BP, Katz ES, et al. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. J Am Coll Cardiol 1994; 23:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/10\">",
"      Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 2010; 122:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/11\">",
"      Hiramoto J, Hansen KJ, Pan XM, et al. Atheroemboli during renal artery angioplasty: an ex vivo study. J Vasc Surg 2005; 41:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/12\">",
"      Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/13\">",
"      Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002; 90:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/14\">",
"      Sharma PV, Babu SC, Shah PM, Nassoura ZE. Changing patterns of atheroembolism. Cardiovasc Surg 1996; 4:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/15\">",
"      Doty JR, Wilentz RE, Salazar JD, et al. Atheroembolism in cardiac surgery. Ann Thorac Surg 2003; 75:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/16\">",
"      Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol 2003; 42:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/17\">",
"      Lin PH, Bush RL, Conklin BS, et al. Late complication of aortoiliac stent placement- atheroembolization of the lower extremities. J Surg Res 2002; 103:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/18\">",
"      Jucgla A, Moreso F, Muniesa C, et al. Cholesterol embolism: still an unrecognized entity with a high mortality rate. J Am Acad Dermatol 2006; 55:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/19\">",
"      Blankenship JC, Butler M, Garbes A. Prospective assessment of cholesterol embolization in patients with acute myocardial infarction treated with thrombolytic vs conservative therapy. Chest 1995; 107:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/20\">",
"      Cross SS. How common is cholesterol embolism? J Clin Pathol 1991; 44:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/21\">",
"      THURLBECK WM, CASTLEMAN B. Atheromatous emboli to the kidneys after aortic surgery. N Engl J Med 1957; 257:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/22\">",
"      Mayo RR, Swartz RD. Redefining the incidence of clinically detectable atheroembolism. Am J Med 1996; 100:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/23\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Independent association of high blood pressure and aortic atherosclerosis: A population-based study. Circulation 2000; 102:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/24\">",
"      Baumann DS, McGraw D, Rubin BG, et al. An institutional experience with arterial atheroembolism. Ann Vasc Surg 1994; 8:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/25\">",
"      Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003; 14:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/26\">",
"      Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation 2007; 116:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/27\">",
"      Carroccio A, Olin JW, Ellozy SH, et al. The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up. J Vasc Surg 2004; 40:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/28\">",
"      Tunick PA, Perez JL, Kronzon I. Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 1991; 115:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/29\">",
"      Karalis DG, Chandrasekaran K, Victor MF, et al. Recognition and embolic potential of intraaortic atherosclerotic debris. J Am Coll Cardiol 1991; 17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/30\">",
"      Tunick PA, Kronzon I. Protruding atherosclerotic plaque in the aortic arch of patients with systemic embolization: a new finding seen by transesophageal echocardiography. Am Heart J 1990; 120:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/31\">",
"      Coy KM, Maurer G, Goodman D, Siegel RJ. Transesophageal echocardiographic detection of aortic atheromatosis may provide clues to occult renal dysfunction in the elderly. Am Heart J 1992; 123:1684.",
"     </a>",
"    </li>",
"    <li>",
"     Koppang JR, Nanda NC, Coghlan C, Sanyal R. Histologically confirmed cholesterol atheroemboli with identification of the source by transesophageal echocardiography. Echocardiography 1992; 9:379. file://onlinelibrary.wiley.com/doi/10.1111/j.1540-8175.1992.tb00481.x/abstract (Accessed on November 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/33\">",
"      Freedberg RS, Tunick PA, Kronzon I. Emboli in transit: the missing link. J Am Soc Echocardiogr 1998; 11:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/34\">",
"      Meissner I, Khandheria BK, Sheps SG, et al. Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol 2004; 44:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/35\">",
"      Tunick PA, Kronzon I. Atherosclerosis of the aorta: a risk factor, risk marker, or an innocent bystander? J Am Coll Cardiol 2005; 45:1907; author reply 1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/36\">",
"      Harloff A, Simon J, Brendecke S, et al. Complex plaques in the proximal descending aorta: an underestimated embolic source of stroke. Stroke 2010; 41:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/37\">",
"      Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/38\">",
"      Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol 1998; 32:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/39\">",
"      Holden A, Hill A, Jaff MR, Pilmore H. Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. Kidney Int 2006; 70:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/40\">",
"      Edwards MS, Craven BL, Stafford J, et al. Distal embolic protection during renal artery angioplasty and stenting. J Vasc Surg 2006; 44:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/41\">",
"      Glassock RJ, Ritz E, Bommer J, et al. Acute renal failure, hypertension and skin necrosis in a patient with streptokinase therapy. Am J Nephrol 1984; 4:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/42\">",
"      Hitti WA, Wali RK, Weinman EJ, et al. Cholesterol embolization syndrome induced by thrombolytic therapy. Am J Cardiovasc Drugs 2008; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/43\">",
"      Nevelsteen A, Kutten M, Lacroix H, Suy R. Oral anticoagulant therapy: a precipitating factor in the pathogenesis of cholesterol embolization? Acta Chir Belg 1992; 92:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/44\">",
"      Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/45\">",
"      Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/46\">",
"      Blackshear JL, Zabalgoitia M, Pennock G, et al. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. Am J Cardiol 1999; 83:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/47\">",
"      Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol 1986; 122:1194.",
"     </a>",
"    </li>",
"    <li>",
"     Olin JW. Other Peripheral Arterial Diseases. In: Goldman: Cecil Textbook of Medicine, 21st ed, WB Saunders, Philadelphia 2000. p.362.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/49\">",
"      Turakhia AK, Khan MA. Splinter hemorrhages as a possible clinical manifestation of cholesterol crystal embolization. J Rheumatol 1990; 17:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/50\">",
"      Donohue KG, Saap L, Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. J Eur Acad Dermatol Venereol 2003; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/51\">",
"      Rosansky SJ. Multiple cholesterol emboli syndrome. South Med J 1982; 75:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/52\">",
"      Quintart C, Treille S, Lefebvre P, Pontus T. Penile necrosis following cholesterol embolism. Br J Urol 1997; 80:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/53\">",
"      Zhang WW, Chauvapun JP, Dosluoglu HH. Scrotal necrosis following endovascular abdominal aortic aneurysm repair. Vascular 2007; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/54\">",
"      Mittal BV, Alexander MP, Rennke HG, Singh AK. Atheroembolic renal disease: a silent masquerader. Kidney Int 2008; 73:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/55\">",
"      Sarwar S, Al-Absi A, Wall BM. Catastrophic cholesterol crystal embolization after endovascular stent placement for peripheral vascular disease. Am J Med Sci 2008; 335:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/56\">",
"      Ben-Horin S, Bardan E, Barshack I, et al. Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism. Am J Gastroenterol 2003; 98:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/57\">",
"      Moolenaar W, Lamers CB. Cholesterol crystal embolization to liver, gallbladder, and pancreas. Dig Dis Sci 1996; 41:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/58\">",
"      Moolenaar W, Lamers CB. Gastrointestinal blood loss due to cholesterol crystal embolization. J Clin Gastroenterol 1995; 21:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/59\">",
"      Bourdages R, Prentice RS, Beck IT, et al. Atheromatous embolization to the stomach: an unusual cause of gastrointestinal bleeding. Am J Dig Dis 1976; 21:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/60\">",
"      Abdelmalek MF, Spittell PC. 79-year-old woman with blue toes. Mayo Clin Proc 1995; 70:292.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. The aorta as a donor source of brain embolism. In: Brain embolism, Caplan, LR, Manning, WJ (Eds), Informa Healthcare, New York 2006. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/62\">",
"      Petty GW, Khandheria BK, Meissner I, et al. Population-based study of the relationship between atherosclerotic aortic debris and cerebrovascular ischemic events. Mayo Clin Proc 2006; 81:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/63\">",
"      Russo C, Jin Z, Rundek T, et al. Atherosclerotic disease of the proximal aorta and the risk of vascular events in a population-based cohort: the Aortic Plaques and Risk of Ischemic Stroke (APRIS) study. Stroke 2009; 40:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/64\">",
"      Cohen A, Tzourio C, Bertrand B, et al. Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. Circulation 1997; 96:3838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/65\">",
"      Di Tullio MR, Russo C, Jin Z, et al. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009; 119:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/66\">",
"      Ezzeddine MA, Primavera JM, Rosand J, et al. Clinical characteristics of pathologically proved cholesterol emboli to the brain. Neurology 2000; 54:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/67\">",
"      HOLLENHORST RW. Significance of bright plaques in the retinal arterioles. JAMA 1961; 178:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/68\">",
"      Chawluk JB, Kushner MJ, Bank WJ, et al. Atherosclerotic carotid artery disease in patients with retinal ischemic syndromes. Neurology 1988; 38:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/69\">",
"      Bunt TJ. The clinical significance of the asymptomatic Hollenhorst plaque. J Vasc Surg 1986; 4:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/70\">",
"      Dunlap AB, Kosmorsky GS, Kashyap VS. The fate of patients with retinal artery occlusion and Hollenhorst plaque. J Vasc Surg 2007; 46:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/71\">",
"      Wijman CA, Babikian VL, Matjucha IC, et al. Cerebral microembolism in patients with retinal ischemia. Stroke 1998; 29:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/72\">",
"      Babikian V, Wijman CA, Koleini B, et al. Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study. Cerebrovasc Dis 2001; 12:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/73\">",
"      Thadhani RI, Camargo CA Jr, Xavier RJ, et al. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore) 1995; 74:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/74\">",
"      Cosio FG, Zager RA, Sharma HM. Atheroembolic renal disease causes hypocomplementaemia. Lancet 1985; 2:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/75\">",
"      Kasinath BS, Lewis EJ. Eosinophilia as a clue to the diagnosis of atheroembolic renal disease. Arch Intern Med 1987; 147:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/76\">",
"      Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med 1991; 91:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/77\">",
"      Tunick PA, Krinsky GA, Lee VS, Kronzon I. Diagnostic imaging of thoracic aortic atherosclerosis. AJR Am J Roentgenol 2000; 174:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/78\">",
"      Tenenbaum A, Garniek A, Shemesh J, et al. Dual-helical CT for detecting aortic atheromas as a source of stroke: comparison with transesophageal echocardiography. Radiology 1998; 208:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/79\">",
"      Khatri IA, Mian N, Alkawi A, et al. Catheter-based aortography fails to identify aortic atherosclerotic lesions detected on transesophageal echocardiography. J Neuroimaging 2005; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/80\">",
"      Warren BA, Vales O. The ultrastructure of the stages of atheroembolic occlusion of renal arteries. Br J Exp Pathol 1973; 54:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/81\">",
"      Case records of the Massachusetts General Hospital. Weekly Clinicopathological Exercises. Case 11-1996. A 69-year-old man with progressive renal failure and the abrupt onset of dyspnea. N Engl J Med 1996; 334:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/82\">",
"      Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/83\">",
"      Mann SJ, Sos TA. Treatment of atheroembolization with corticosteroids. Am J Hypertens 2001; 14:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/84\">",
"      Motegi S, Abe M, Shimizu A, et al. Cholesterol crystal embolization: skin manifestation, gastrointestinal and central nervous symptom treated with corticosteroid. J Dermatol 2005; 32:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/85\">",
"      Matsumura T, Matsumoto A, Ohno M, et al. A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids. Am J Med Sci 2006; 331:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/86\">",
"      Koga J, Ohno M, Okamoto K, et al. Cholesterol embolization treated with corticosteroids--two case reports. Angiology 2005; 56:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/87\">",
"      Y&uuml;cel AE, Kart-K&ouml;seoglu H, Demirhan B, Ozdemir FN. Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases. Rheumatol Int 2006; 26:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/88\">",
"      Fabbian F, Catalano C, Lambertini D, et al. A possible role of corticosteroids in cholesterol crystal embolization. Nephron 1999; 83:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/89\">",
"      Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ 2002; 324:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/90\">",
"      Minatohara K. Renal failure associated with blue toe syndrome: effective treatment with intravenous prostaglandin E-1. Acta Derm Venereol 2006; 86:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/91\">",
"      Hasegawa M, Sugiyama S. Apheresis in the treatment of cholesterol embolic disease. Ther Apher Dial 2003; 7:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/92\">",
"      Tamura K, Umemura M, Yano H, et al. Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan. Clin Exp Nephrol 2003; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/93\">",
"      Muso E, Mune M, Fujii Y, et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001; 89:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/94\">",
"      Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation 2006; 114:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/95\">",
"      Fujimoto S, Yasaka M, Otsubo R, et al. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004; 35:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/96\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     Aortic Arch Related Cerebral Hazard Trial (ARCH). www.clinicaltrials.gov/ct/show/NCT00235248 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     file://packageinserts.bms.com/pi/pi_coumadin.pdf (Accessed on October 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/99\">",
"      Keen RR, McCarthy WJ, Shireman PK, et al. Surgical management of atheroembolization. J Vasc Surg 1995; 21:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/100\">",
"      Renshaw A, McCowen T, Waltke EA, et al. Angioplasty with stenting is effective in treating blue toe syndrome. Vasc Endovascular Surg 2002; 36:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/101\">",
"      Kumins NH, Owens EL, Oglevie SB, et al. Early experience using the Wallgraft in the management of distal microembolism from common iliac artery patholology. Ann Vasc Surg 2002; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/102\">",
"      Matchett WJ, McFarland DR, Eidt JF, Moursi MM. Blue toe syndrome: treatment with intra-arterial stents and review of therapies. J Vasc Interv Radiol 2000; 11:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/15/31994/abstract/103\">",
"      Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8184 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-5AC2A9890B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31994=[""].join("\n");
var outline_f31_15_31994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5886720\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5888108\">",
"      ATHEROEMBOLISM VERSUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5888585\">",
"      Risk factors for aortic atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503780\">",
"      - Plaque characteristics and location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503787\">",
"      - Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503824\">",
"      - Anticoagulation/thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1505321\">",
"      - Livedo reticularis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H120148342\">",
"      - Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H395442939\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184668148\">",
"      - Ocular signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1505795\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5888663\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5889574\">",
"      Biopsy and pathologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5889718\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120149438\">",
"      Risk factor management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1503064\">",
"      Managing ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1503460\">",
"      Preventing recurrent embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1506317\">",
"      - Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503486\">",
"      - Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Plaque removal or exclusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17713880\">",
"      - Covered stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1506544\">",
"      - Revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5890461\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5886720\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8184|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/23/7540\" title=\"diagnostic image 1\">",
"      Complex atherosclerotic plaque in the thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/21/33110\" title=\"diagnostic image 2\">",
"      Cholesterol emboli in transit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/39/21104\" title=\"diagnostic image 3\">",
"      Thoracic aortic plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/2/1059\" title=\"diagnostic image 4\">",
"      Severe aortic plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/1/4118\" title=\"diagnostic image 5\">",
"      Atherosclerotic plaque on CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/4/26690\" title=\"diagnostic image 6\">",
"      Aortic atherosclerosis on MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8184|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/61/3028\" title=\"picture 1\">",
"      Autopsy specimen atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/58/40866\" title=\"picture 2\">",
"      Livedo reticularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/15/2289\" title=\"picture 3\">",
"      Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/25/9622\" title=\"picture 4A\">",
"      Renal atheroembolus histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/38/35427\" title=\"picture 4B\">",
"      Renal atheroembolus toluidine blue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/3/23601\" title=\"picture 5\">",
"      Hollenhorst plaque retinal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/12/15554\" title=\"picture 6\">",
"      Atherosclerotic plaque visualized by 3D TEE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8184|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?35/57/36767\" title=\"movie 1\">",
"      Atheroma 2D TEE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?23/31/24063\" title=\"movie 2\">",
"      Atheroma on 3D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?29/60/30659\" title=\"movie 3\">",
"      Atheroma on CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=related_link\">",
"      Clinical presentation, evaluation, and treatment of renal atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11367?source=related_link\">",
"      Diagnosis and treatment of renal infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12245?source=related_link\">",
"      Overview of upper extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_15_31995="ORT replacement guide PI";
var content_f31_15_31995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of oral rehydration solution to give child (over 4 hours) for mild dehydration, based on weight",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       English system",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Metric system",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Weight, lbs",
"      </td>",
"      <td class=\"subtitle2\">",
"       Volume, ounces",
"      </td>",
"      <td class=\"subtitle2\">",
"       Weight, kilograms",
"      </td>",
"      <td class=\"subtitle2\">",
"       Volume, milliliters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       7.5",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       200",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       11.5",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       300",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       400",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       500",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       22.5",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       600",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       26.5",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       700",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       800",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       900",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31995=[""].join("\n");
var outline_f31_15_31995=null;
var title_f31_15_31996="Screening tests for CRC";
var content_f31_15_31996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the characteristics of screening tests for colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Screening test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test performance (sensitivity, specificity)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Complexity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential effectiveness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evidence of effectiveness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Screening test risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal occult blood test",
"       </td>",
"       <td>",
"        Intermediate for cancers, low for polyps",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"       <td>",
"        Strongest",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal immunochemical test for hemoglobin",
"       </td>",
"       <td>",
"        Intermediate for cancers, low for polyps",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexible sigmoidoscopy",
"       </td>",
"       <td>",
"        High for up to half of the colon",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOBT + flexible sigmoidoscopy",
"       </td>",
"       <td>",
"        Same as flexible sigmoidoscopy and FOBT",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Double contrast barium enema",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Computed tomographic colonography",
"       </td>",
"       <td>",
"        High (similar to colonoscopy)",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The costs of the screening tests themselves, also an important characteristic, vary, but the costs of the screening strategies (lifetime programs of screening and follow-up of abnormal test results) are comparable. Complexity involves patient preparation, inconvenience, facilities and equipment needed, and patient discomfort.",
"    </div>",
"    <div class=\"reference\">",
"     Data updated according to joint multi-society guidelines 2008. Adapted from Winawer, SW, Fletcher, RH, Mille, L, et al. AGA guidelines: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997; 112: 594.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31996=[""].join("\n");
var outline_f31_15_31996=null;
var title_f31_15_31997="Type 1 vs type 2 DM";
var content_f31_15_31997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of type 1 and type 2 diabetes mellitus in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 1 diabetes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 2 diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prevalence",
"        </strong>",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Increasing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Age at presentation",
"        </strong>",
"       </td>",
"       <td>",
"        Throughout childhood",
"       </td>",
"       <td>",
"        Puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Onset",
"        </strong>",
"       </td>",
"       <td>",
"        Acute severe",
"       </td>",
"       <td>",
"        Insidious to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ketosis at onset",
"        </strong>",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        About one-third*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Affected relative",
"        </strong>",
"       </td>",
"       <td>",
"        5 to 10 percent",
"       </td>",
"       <td>",
"        75 to 90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Female:male",
"        </strong>",
"       </td>",
"       <td>",
"        1:1",
"       </td>",
"       <td>",
"        ~2:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Inheritance",
"        </strong>",
"       </td>",
"       <td>",
"        Polygenic",
"       </td>",
"       <td>",
"        Polygenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         HLA-DR3/4",
"        </strong>",
"       </td>",
"       <td>",
"        Strong association",
"       </td>",
"       <td>",
"        No association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ethnicity",
"        </strong>",
"       </td>",
"       <td>",
"        Most common in non-Hispanic white",
"       </td>",
"       <td>",
"        All",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Insulin secretion",
"        </strong>",
"       </td>",
"       <td>",
"        Decreased/absent",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Insulin sensitivity",
"        </strong>",
"       </td>",
"       <td>",
"        Normal when controlled",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Insulin dependence",
"        </strong>",
"       </td>",
"       <td>",
"        Permanent",
"       </td>",
"       <td>",
"        Episodic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Obese or overweight",
"        </strong>",
"       </td>",
"       <td>",
"        20 to 25 percent overweight",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;80 percent obese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Acanthosis nigricans",
"        </strong>",
"       </td>",
"       <td>",
"        12 percent",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        50 to 90 percent",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pancreatic antibodies",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reported frequency of ketonuria or ketoacidosis at time of diagnosis of T2DM varies widely.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     In North America, type 2 diabetes mellitus (T2DM) predominates in Hispanic, African-American, Native-American, Canadian First Nation, Pacific Islander, and Asian-American youth.",
"     <sup>",
"      [1]",
"     </sup>",
"     <br/>",
"     &Delta; With increased prevalence of childhood overweight, 20 to 25 percent of newly diagnosed children with type 1 diabetes mellitus (T1DM) are overweight, which is higher than the prevalence of",
"     <em>",
"      overweight",
"     </em>",
"     in a similar population without T1DM. However, the prevalence of",
"     <em>",
"      obesity",
"     </em>",
"     is not increased among children and adolescents with T1DM.",
"     <sup>",
"      [2]",
"     </sup>",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     These frequencies of acanthosis nigricans are based on a registry study in the United States. Populations with lower rates of obesity or different ethnic mixes may have different results.",
"     <sup>",
"      [3]",
"     </sup>",
"     <br/>",
"     &sect; Autoantibodies to insulin (IAA), islet cell cytoplasm (ICA), glutamic acid decarboxylase (GAD), tyrosine phosphatase (insulinoma associated) antibody (IA-2 and IA-2&beta;), or zinc channel antibody (ZnT8) are present at diagnosis in 85 to 98 percent of patients with T1DM.",
"     <sup>",
"      [3,4]",
"     </sup>",
"     <br/>",
"     &yen; One study reported that 9.8 percent of youth with phenotypic type 2 diabetes mellitus have pancreatic antibodies to IA-2 and/or GAD.",
"     <sup>",
"      [5]",
"     </sup>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Mayer-Davis EJ, Bell RA, Dabelea D, et al. The many faces of diabetes in American youth: type 1 and type 2 diabetes in five race and ethnic populations: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 Suppl 2:S99.",
"      </li>",
"      <li>",
"       Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010; 11:4.",
"      </li>",
"      <li>",
"       Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 2011; 34:1628.",
"      </li>",
"      <li>",
"       Steck AK, Johnson K, Barriga KJ. Age of Islet Autoantibody Appearance and Mean Levels of Insulin, but Not GAD or IA-2 Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes. Diabetes Care 2011; 34:1397.",
"      </li>",
"      <li>",
"       Klingensmith GJ, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33:1970.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31997=[""].join("\n");
var outline_f31_15_31997=null;
var title_f31_15_31998="Optimal PD regimen and PET";
var content_f31_15_31998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Optimal PD regimen and peritoneal equilibration test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm showing how the results of the peritoneal equilibration test may help guide the choice of an optimal peritoneal dialysis regimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31998=[""].join("\n");
var outline_f31_15_31998=null;
var title_f31_15_31999="Apical 4 chamber right atrial tumor";
var content_f31_15_31999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right atrial tumor seen on transthoracic echocardiography from the apical 4 chamber view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view shows a tumor mass (arrows) extending into the right ventricle (RV) from the right atrium (RA). This large mass occupies most of the RA and extends across the tricuspid valve into the inlet portion of the RV. Finding a mass of this sort should direct the examination at the inferior vena cava because an abdominal malignancy with intravascular extension is the usual origin. This particular tumor was a renal cell carcinoma.",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_15_31999=[""].join("\n");
var outline_f31_15_31999=null;
